Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	DNA-binding transcription activator activity, RNA polymerase II-specific	SOX1 SOX3 HNF1A VENTX CEBPB NFATC3 DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 PRDM16 EBF4 FOXC2	4.88e-10	560	68	15	GO:0001228
GeneOntologyMolecularFunction	DNA-binding transcription activator activity	SOX1 SOX3 HNF1A VENTX CEBPB NFATC3 DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 PRDM16 EBF4 FOXC2	5.66e-10	566	68	15	GO:0001216
GeneOntologyMolecularFunction	RNA polymerase II cis-regulatory region sequence-specific DNA binding	SOX1 SOX3 HIVEP3 HNF1A ZNF219 VENTX CEBPB PER2 NFATC3 GLI3 DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 PRDM16 EBF4 ZNF513 FOXC2	3.09e-09	1244	68	20	GO:0000978
GeneOntologyMolecularFunction	cis-regulatory region sequence-specific DNA binding	SOX1 SOX3 HIVEP3 HNF1A ZNF219 VENTX CEBPB PER2 NFATC3 GLI3 DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 PRDM16 EBF4 ZNF513 FOXC2	4.46e-09	1271	68	20	GO:0000987
GeneOntologyMolecularFunction	RNA polymerase II transcription regulatory region sequence-specific DNA binding	SOX1 SOX3 HIVEP3 HNF1A ZNF219 VENTX CEBPB PER2 NFATC3 GLI3 DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 PRDM16 CREBBP EBF4 ZNF513 FOXC2	7.98e-09	1459	68	21	GO:0000977
GeneOntologyMolecularFunction	DNA-binding transcription factor activity, RNA polymerase II-specific	SOX1 SOX3 HIVEP3 HNF1A ZNF219 VENTX CEBPB NFATC3 GLI3 DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 PRDM16 EBF4 ZNF513 FOXC2	1.45e-07	1412	68	19	GO:0000981
GeneOntologyMolecularFunction	transcription factor binding	DCAF1 MAGEA2 HNF1A CEBPB PER2 NFATC3 NACA ID4 NR4A1 RUNX1 PRDM16 CIT CREBBP EBF4	1.94e-07	753	68	14	GO:0008134
GeneOntologyMolecularFunction	DNA-binding transcription factor binding	DCAF1 MAGEA2 CEBPB PER2 ID4 NR4A1 RUNX1 PRDM16 CREBBP EBF4	2.60e-05	582	68	10	GO:0140297
GeneOntologyMolecularFunction	transcription coactivator binding	HNF1A RUNX1 CIT CREBBP	3.42e-05	54	68	4	GO:0001223
GeneOntologyMolecularFunction	transcription coregulator binding	HNF1A PER2 RUNX1 CIT CREBBP	1.15e-04	140	68	5	GO:0001221
GeneOntologyMolecularFunction	chromatin binding	HNF1A CEBPB TOX NFATC3 GLI3 DLX2 RUNX1 MBD6 CREBBP FOXC2	1.89e-04	739	68	10	GO:0003682
GeneOntologyMolecularFunction	SMAD binding	MAGI2 PRDM16 CREBBP PML	2.12e-04	86	68	4	GO:0046332
GeneOntologyMolecularFunction	transcription coactivator activity	CITED4 PER2 NACA PRDM16 CREBBP PML	5.77e-04	303	68	6	GO:0003713
GeneOntologyMolecularFunction	histone deacetylase binding	MAGEA2 CEBPB PER2 GLI3	1.59e-03	147	68	4	GO:0042826
GeneOntologyMolecularFunction	nuclear glucocorticoid receptor binding	CEBPB NR4A1	2.09e-03	20	68	2	GO:0035259
GeneOntologyMolecularFunction	protein heterodimerization activity	HNF1A CEBPB CREB3L3 NR4A1 RUNX1 PML	2.33e-03	398	68	6	GO:0046982
GeneOntologyMolecularFunction	chromatin DNA binding	CEBPB TOX CREBBP FOXC2	2.54e-03	167	68	4	GO:0031490
GeneOntologyMolecularFunction	RNA polymerase II-specific DNA-binding transcription factor binding	DCAF1 CEBPB PER2 ID4 NR4A1 CREBBP	2.94e-03	417	68	6	GO:0061629
GeneOntologyMolecularFunction	transcription coregulator activity	IRF2BP2 CITED4 PER2 NACA PRDM16 CREBBP PML	2.96e-03	562	68	7	GO:0003712
GeneOntologyMolecularFunction	nuclear receptor binding	DCAF1 CEBPB PER2 NR4A1	3.80e-03	187	68	4	GO:0016922
GeneOntologyMolecularFunction	histone acetyltransferase binding	CEBPB GLI3	4.37e-03	29	68	2	GO:0035035
GeneOntologyBiologicalProcess	positive regulation of transcription by RNA polymerase II	SOX1 SOX3 HNF1A ZNF219 VENTX CEBPB TOX NFATC3 GLI3 NACA ID4 DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 PRDM16 CREBBP EBF4 ZNF513 FOXC2	5.38e-10	1390	70	22	GO:0045944
GeneOntologyBiologicalProcess	negative regulation of transcription by RNA polymerase II	SOX1 DCAF1 SOX3 MAGEA2 IRF2BP2 HNF1A ZNF219 CEBPB PER2 NFATC3 GLI3 NACA ID4 DLX2 RUNX1 PRDM16 CREBBP FOXC2	8.94e-09	1053	70	18	GO:0000122
GeneOntologyBiologicalProcess	negative regulation of DNA-templated transcription	SOX1 DCAF1 SOX3 MAGEA2 IRF2BP2 HNF1A ZNF219 CEBPB PER2 NFATC3 GLI3 NACA ID4 DLX2 RUNX1 PRDM16 CREBBP PML FOXC2	1.26e-07	1399	70	19	GO:0045892
GeneOntologyBiologicalProcess	negative regulation of RNA biosynthetic process	SOX1 DCAF1 SOX3 MAGEA2 IRF2BP2 HNF1A ZNF219 CEBPB PER2 NFATC3 GLI3 NACA ID4 DLX2 RUNX1 PRDM16 CREBBP PML FOXC2	1.47e-07	1413	70	19	GO:1902679
GeneOntologyBiologicalProcess	negative regulation of neuron differentiation	SOX3 GLI3 ID4 DLX2 CIT	1.69e-05	94	70	5	GO:0045665
GeneOntologyBiologicalProcess	T cell differentiation in thymus	TNFRSF9 TOX NFATC3 GLI3 ANKLE1	4.29e-05	114	70	5	GO:0033077
GeneOntologyBiologicalProcess	negative regulation of developmental process	SOX3 EFNB3 ADAMTS7 ATXN2 NFATC3 BICRA GLI3 ID4 DLX2 RUNX1 PRDM16 CIT PML FOXC2	5.09e-05	1220	70	14	GO:0051093
GeneOntologyBiologicalProcess	protein acetylation	MAGEA2 ATAT1 CREBBP PML	8.41e-05	68	70	4	GO:0006473
GeneOntologyBiologicalProcess	central nervous system neuron differentiation	SOX1 TOX ATXN2 GLI3 ID4 DLX2	9.47e-05	217	70	6	GO:0021953
GeneOntologyBiologicalProcess	peptidyl-lysine acetylation	ATAT1 CREBBP PML	1.15e-04	28	70	3	GO:0018394
GeneOntologyBiologicalProcess	limbic system development	SOX3 GLI3 ID4 DLX2 ATAT1	1.18e-04	141	70	5	GO:0021761
GeneOntologyBiologicalProcess	thymic T cell selection	TOX NFATC3 GLI3	1.28e-04	29	70	3	GO:0045061
GeneOntologyBiologicalProcess	cerebral cortex neuron differentiation	TOX ID4 DLX2	1.28e-04	29	70	3	GO:0021895
GeneOntologyBiologicalProcess	cell fate commitment	SOX1 TOX GLI3 DLX2 RUNX1 PML FOXC2	1.48e-04	338	70	7	GO:0045165
GeneOntologyBiologicalProcess	connective tissue development	ZNF219 ADAMTS7 GLI3 ID4 DLX2 RUNX1 FOXC2	1.61e-04	343	70	7	GO:0061448
GeneOntologyBiologicalProcess	negative regulation of cell differentiation	SOX3 EFNB3 ADAMTS7 NFATC3 BICRA GLI3 ID4 DLX2 RUNX1 PRDM16 CIT	1.65e-04	875	70	11	GO:0045596
GeneOntologyBiologicalProcess	negative regulation of cell development	EFNB3 GLI3 ID4 DLX2 RUNX1 PRDM16 CIT	1.93e-04	353	70	7	GO:0010721
GeneOntologyBiologicalProcess	neuron fate commitment	SOX1 GLI3 DLX2 RUNX1	2.60e-04	91	70	4	GO:0048663
GeneOntologyBiologicalProcess	regulation of cell development	CEBPB EFNB3 PER2 TOX GLI3 NACA ID4 DLX2 ANKLE1 RUNX1 PRDM16 CIT	2.89e-04	1095	70	12	GO:0060284
GeneOntologyBiologicalProcess	mononuclear cell differentiation	DCAF1 IRF2BP2 TNFRSF9 CEBPB TOX NFATC3 GLI3 ANKLE1 RUNX1	3.03e-04	640	70	9	GO:1903131
GeneOntologyBiologicalProcess	cell fate specification involved in pattern specification	SOX1 GLI3	3.14e-04	8	70	2	GO:0060573
GeneOntologyBiologicalProcess	ventral spinal cord interneuron specification	SOX1 GLI3	3.14e-04	8	70	2	GO:0021521
GeneOntologyBiologicalProcess	positive regulation of vascular wound healing	FOXC2 VEGFB	3.14e-04	8	70	2	GO:0035470
GeneOntologyBiologicalProcess	leukocyte differentiation	DCAF1 IRF2BP2 TNFRSF9 CEBPB TOX NFATC3 GLI3 ANKLE1 RUNX1 PRDM16	3.15e-04	789	70	10	GO:0002521
GeneOntologyBiologicalProcess	paraxial mesoderm formation	HNF1A FOXC2	4.02e-04	9	70	2	GO:0048341
GeneOntologyBiologicalProcess	lymphocyte differentiation	DCAF1 IRF2BP2 TNFRSF9 TOX NFATC3 GLI3 ANKLE1 RUNX1	4.58e-04	537	70	8	GO:0030098
GeneOntologyBiologicalProcess	fat cell differentiation	CEBPB PER2 ID4 NR4A1 ATAT1 PRDM16	4.61e-04	291	70	6	GO:0045444
GeneOntologyBiologicalProcess	hippocampus development	GLI3 ID4 DLX2 ATAT1	5.00e-04	108	70	4	GO:0021766
GeneOntologyBiologicalProcess	protein acylation	MAGEA2 ATAT1 CREBBP PML	5.00e-04	108	70	4	GO:0043543
GeneOntologyBiologicalProcess	gland development	SOX3 HNF1A CEBPB NFATC3 GLI3 ID4 RUNX1 PML	5.90e-04	558	70	8	GO:0048732
GeneOntologyBiologicalProcess	ventral spinal cord interneuron fate commitment	SOX1 GLI3	7.33e-04	12	70	2	GO:0060579
GeneOntologyBiologicalProcess	cell fate commitment involved in pattern specification	SOX1 GLI3	7.33e-04	12	70	2	GO:0060581
GeneOntologyBiologicalProcess	embryonic cranial skeleton morphogenesis	GLI3 DLX2 FOXC2	7.34e-04	52	70	3	GO:0048701
GeneOntologyCellularComponent	chromatin	SOX1 SOX3 HNF1A VENTX CEBPB NFATC3 BICRA DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 CREBBP EBF4 FOXC2	2.36e-05	1480	70	16	GO:0000785
GeneOntologyCellularComponent	transcription regulator complex	HNF1A CEBPB PER2 NFATC3 GLI3 NR4A1 MLXIP RUNX1 PRDM16 CREBBP	2.80e-05	596	70	10	GO:0005667
Domain	SOXp	SOX1 SOX3	1.26e-04	5	67	2	PF12336
Domain	SOX_fam	SOX1 SOX3	1.26e-04	5	67	2	IPR022097
Domain	BRLZ	CEBPB CREB3L3 CREB3L4	8.60e-04	52	67	3	SM00338
Domain	HMG_box	SOX1 SOX3 TOX	9.09e-04	53	67	3	PF00505
Domain	BZIP	CEBPB CREB3L3 CREB3L4	9.09e-04	53	67	3	PS50217
Domain	bZIP	CEBPB CREB3L3 CREB3L4	9.60e-04	54	67	3	IPR004827
Domain	HMG_BOX_2	SOX1 SOX3 TOX	9.60e-04	54	67	3	PS50118
Domain	HMG	SOX1 SOX3 TOX	9.60e-04	54	67	3	SM00398
Domain	-	SOX1 SOX3 TOX	1.01e-03	55	67	3	1.10.30.10
Domain	HMG_box_dom	SOX1 SOX3 TOX	1.64e-03	65	67	3	IPR009071
Domain	IPT	NFATC3 EBF4	4.20e-03	27	67	2	SM00429
Domain	TIG	NFATC3 EBF4	5.51e-03	31	67	2	PF01833
Domain	RA	RIN2 RGL2	5.51e-03	31	67	2	SM00314
Domain	IPT	NFATC3 EBF4	5.87e-03	32	67	2	IPR002909
Domain	bZIP_1	CREB3L3 CREB3L4	6.60e-03	34	67	2	PF00170
Domain	RA	RIN2 RGL2	7.38e-03	36	67	2	PF00788
Domain	RA	RIN2 RGL2	7.79e-03	37	67	2	PS50200
Domain	TF_DNA-bd	CREB3L3 CREB3L4	7.79e-03	37	67	2	IPR008917
Domain	HLH	ID4 MLXIP EBF4	8.38e-03	116	67	3	SM00353
Domain	RA_dom	RIN2 RGL2	9.06e-03	40	67	2	IPR000159
Domain	Kinesin-like_fam	KIF26B KIFC3	1.04e-02	43	67	2	IPR027640
Pathway	KEGG_MEDICUS_PATHOGEN_HBV_HBX_TO_CREB_MEDIATED_TRANSCRIPTION	CREB3L3 CREB3L4 CREBBP	1.10e-05	13	49	3	M47595
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_PRKACA_TO_ACTH_CORTISOL_SIGNALING_PATHWAY	CREB3L3 NR4A1 CREB3L4	2.59e-05	17	49	3	M47514
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_PRKAR1A_TO_ACTH_CORTISOL_SIGNALING_PATHWAY	CREB3L3 NR4A1 CREB3L4	3.10e-05	18	49	3	M47516
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_PDE11A_PDE8B_TO_ACTH_CORTISOL_SIGNALING_PATHWAY	CREB3L3 NR4A1 CREB3L4	4.32e-05	20	49	3	M47517
Pathway	WP_OREXIN_RECEPTOR_PATHWAY	PER2 TOX ID4 NR4A1 RUNX1 PRDM16	6.37e-05	200	49	6	M48048
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_GNAS_TO_ACTH_CORTISOL_SIGNALING_PATHWAY	CREB3L3 NR4A1 CREB3L4	1.35e-04	29	49	3	M47515
Pathway	KEGG_MEDICUS_VARIANT_CYP11B1_CYP11B2_FUSION_TO_ACTH_CORTISOL_SIGNALING_PATHWAY	CREB3L3 NR4A1 CREB3L4	1.66e-04	31	49	3	M47507
Pathway	KEGG_MEDICUS_REFERENCE_ACTH_CORTISOL_SIGNALING_PATHWAY	CREB3L3 NR4A1 CREB3L4	1.82e-04	32	49	3	M47506
Pathway	REACTOME_RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_DIFFERENTIATION_OF_MYELOID_CELLS	RUNX1 CREBBP	2.46e-04	7	49	2	M27799
Pathway	REACTOME_CREB3_FACTORS_ACTIVATE_GENES	CREB3L3 CREB3L4	4.20e-04	9	49	2	M27773
Pathway	WP_HEART_DEVELOPMENT	NFATC3 FOXC2 VEGFB	5.39e-04	46	49	3	MM15884
Pathway	WP_HEART_DEVELOPMENT	NFATC3 FOXC2 VEGFB	5.75e-04	47	49	3	M39610
Pathway	REACTOME_ACTIVATION_OF_THE_TFAP2_AP_2_FAMILY_OF_TRANSCRIPTION_FACTORS	CITED4 CREBBP	7.64e-04	12	49	2	M27765
Pathway	PID_NFAT_3PATHWAY	NFATC3 NR4A1 CREBBP	8.18e-04	53	49	3	M113
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_CREB_MEDIATED_TRANSCRIPTION	CREB3L3 CREB3L4	9.01e-04	13	49	2	M47674
Pubmed	A census of human transcription factors: function, expression and evolution.	SOX1 SOX3 HIVEP3 HNF1A VENTX CEBPB NFATC3 GLI3 ID4 DLX2 CREB3L3 NR4A1 MLXIP RUNX1 CREB3L4 EBF4 FOXC2	2.26e-12	908	70	17	19274049
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	HIVEP3 PHLDB1 CEBPB PER2 ADAMTS7 BICRA INTS1 NINL SAC3D1 DLX2 ANKLE1 KIFC3 MLXIP MBD6 RGL2 PRDM16 CIT ZNF687	4.63e-12	1105	70	18	35748872
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	SOX1 SOX3 HIVEP3 HNF1A CITED4 ZNF219 TOX GLI3 CREB3L3 CREB3L4 PRDM16 ZNF687 PML ZNF513	6.93e-10	808	70	14	20412781
Pubmed	An atlas of combinatorial transcriptional regulation in mouse and man.	HNF1A CITED4 ZNF219 VENTX PER2 NFATC3 GLI3 ID4 DLX2 MLXIP CREBBP EBF4 PML ZNF513	1.98e-09	877	70	14	20211142
Pubmed	Sox2 and Pax6 maintain the proliferative and developmental potential of gliogenic neural stem cells In vitro.	SOX1 SOX3 GLI3 DLX2	1.48e-08	14	70	4	21766338
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	HNF1A CITED4 ZNF219 PER2 TOX GLI3 ID4 NR4A1 PRDM16 CREBBP ZNF687 FOXC2	1.70e-08	709	70	12	22988430
Pubmed	Human transcription factor protein interaction networks.	IRF2BP2 HNF1A MAP7D1 ATXN2 NFATC3 BICRA GLI3 NACA ID4 MBD6 SRRM2 PRDM16 CIT CREBBP ZNF687 PML	1.85e-08	1429	70	16	35140242
Pubmed	Sox2 is required for embryonic development of the ventral telencephalon through the activation of the ventral determinants Nkx2.1 and Shh.	SOX1 SOX3 GLI3 DLX2	3.51e-08	17	70	4	23444355
Pubmed	Physical and functional link of the leukemia-associated factors AML1 and PML.	RUNX1 CREBBP PML	2.72e-07	7	70	3	15331439
Pubmed	Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.	GLI3 NR4A1 RUNX1 PARD3 CREB3L4 CREBBP PML VEGFB	8.25e-07	371	70	8	25241761
Pubmed	Crumbs2 mediates ventricular layer remodelling to form the spinal cord central canal.	SOX1 SOX3 PARD3	9.28e-07	10	70	3	32150534
Pubmed	Impact of cytosine methylation on DNA binding specificities of human transcription factors.	SOX3 VENTX CEBPB NFATC3 GLI3 DLX2 NR4A1 CREB3L4 FOXC2	1.46e-06	544	70	9	28473536
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	DCAF1 MAGI2 CRACD PHLDB1 MAP7D1 PER2 MLXIP SRRM2	1.65e-06	407	70	8	12693553
Pubmed	Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis.	MAGI2 PARD3	3.99e-06	2	70	2	17989107
Pubmed	CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter.	CEBPB RUNX1	3.99e-06	2	70	2	8622667
Pubmed	C/EBPB-CITED4 in Exercised Heart.	CITED4 CEBPB	3.99e-06	2	70	2	29098625
Pubmed	RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.	RUNX1 PRDM16	3.99e-06	2	70	2	18202228
Pubmed	Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML.	RUNX1 PRDM16	3.99e-06	2	70	2	16598304
Pubmed	Nur77 nuclear import and its NBRE-binding activity in thymic lymphoma cells are regulated by different mechanisms sensitive to FK506 or HA1004.	CHCHD10 NR4A1	3.99e-06	2	70	2	16051191
Pubmed	Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling.	CREBBP PML	3.99e-06	2	70	2	10077561
Pubmed	Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions.	NR4A1 PML	3.99e-06	2	70	2	12032831
Pubmed	An assessment of progress in the use of alternatives in toxicity testing since the publication of the report of the second FRAME Toxicity Committee (1991).	CREBBP PML	3.99e-06	2	70	2	12234245
Pubmed	Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?	RUNX1 PRDM16	3.99e-06	2	70	2	18767145
Pubmed	Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma.	CREBBP PML	3.99e-06	2	70	2	12142048
Pubmed	DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway.	DCAF1 PARD3	3.99e-06	2	70	2	38711082
Pubmed	Sequential genome-wide CRISPR-Cas9 screens identify genes regulating cell-surface expression of tetraspanins.	MAGI2 HNF1A KIF26B BICRA NINL C11orf87 ANKLE1 CREB3L3 PARD3 VEGFB	6.31e-06	832	70	10	36724073
Pubmed	Gli3 is required for the specification and differentiation of preplate neurons.	GLI3 DLX2 PARD3	7.39e-06	19	70	3	16168404
Pubmed	Cell-autonomous activation of Hedgehog signaling inhibits brown adipose tissue development.	CEBPB GLI3 PRDM16	7.39e-06	19	70	3	25848030
Pubmed	MKRN2 Physically Interacts with GLE1 to Regulate mRNA Export and Zebrafish Retinal Development.	MAGI2 ATXN2 GLI3 ID4 DLX2 PARD3 SRRM2	7.93e-06	358	70	7	32460013
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	PHLDB1 MAP7D1 NFATC3 KIF26B MLXIP ATAT1 PARD3 SRRM2 RGL2 PML	8.51e-06	861	70	10	36931259
Pubmed	Distinct SoxB1 networks are required for naïve and primed pluripotency.	SOX1 SOX3	1.20e-05	3	70	2	29256862
Pubmed	Mediator modulates Gli3-dependent Sonic hedgehog signaling.	GLI3 CREBBP	1.20e-05	3	70	2	17000779
Pubmed	Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3.	GLI3 CREBBP	1.20e-05	3	70	2	10075717
Pubmed	Genetic disruption of ATAT1 causes RhoA downregulation through abnormal truncation of C/EBPβ.	CEBPB ATAT1	1.20e-05	3	70	2	38835115
Pubmed	MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.	MAGEA2 PML	1.20e-05	3	70	2	22117195
Pubmed	C/EBPbeta activates E2F-regulated genes in vivo via recruitment of the coactivator CREB-binding protein/P300.	CEBPB CREBBP	1.20e-05	3	70	2	17599912
Pubmed	Transcriptional coactivators CBP and p300 cooperatively enhance HNF-1alpha-mediated expression of the albumin gene in hepatocytes.	HNF1A CREBBP	1.20e-05	3	70	2	15598887
Pubmed	Nuclear-cytoplasmic shuttling of a RING-IBR protein RBCK1 and its functional interaction with nuclear body proteins.	CREBBP PML	1.20e-05	3	70	2	15833741
Pubmed	Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.	CEBPB RUNX1	1.20e-05	3	70	2	11257229
Pubmed	Frequency and clinical impact of ETV6/RUNX1, AF4-MLL, and BCR/ABL fusion genes on features of acute lymphoblastic leukemia at presentation.	AFF1 RUNX1	1.20e-05	3	70	2	26856288
Pubmed	CCAAT/Enhancer-binding protein beta DNA binding is auto-inhibited by multiple elements that also mediate association with p300/CREB-binding protein (CBP).	CEBPB CREBBP	1.20e-05	3	70	2	20452968
Pubmed	Zinc transporter ZIP13 suppresses beige adipocyte biogenesis and energy expenditure by regulating C/EBP-β expression.	CEBPB PRDM16	1.20e-05	3	70	2	28854265
Pubmed	Aβ-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer's disease.	PER2 CREBBP	1.20e-05	3	70	2	25888034
Pubmed	α-MSH and Foxc2 promote fatty acid oxidation through C/EBPβ negative transcription in mice adipose tissue.	CEBPB FOXC2	1.20e-05	3	70	2	27819350
Pubmed	Impact of Ataxin-2 knock out on circadian locomotor behavior and PER immunoreaction in the SCN of mice.	PER2 ATXN2	1.20e-05	3	70	2	27791392
Pubmed	Replication of genetic variation in the MYO9B gene in Crohn's disease.	MAGI2 PARD3	1.20e-05	3	70	2	21515326
Pubmed	PML-nuclear bodies are involved in cellular serum response.	CREBBP PML	1.20e-05	3	70	2	12622724
Pubmed	Intestinal barrier gene variants may not explain the increased levels of antigliadin antibodies, suggesting other mechanisms than altered permeability.	MAGI2 PARD3	1.20e-05	3	70	2	20096742
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	IRF2BP2 MAP7D1 CEBPB ATXN2 BICRA RUNX1 SRRM2 CIT CREBBP ZNF687 PML	1.21e-05	1103	70	11	34189442
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	DCAF1 MAP7D1 ZNF219 BICRA GLI3 PARD3 SRRM2 PRDM16 CREBBP ZNF687 PML	1.35e-05	1116	70	11	31753913
Pubmed	Ofd1 controls dorso-ventral patterning and axoneme elongation during embryonic brain development.	GLI3 DLX2 PARD3	1.96e-05	26	70	3	23300826
Pubmed	CBP-CITED4 is required for luteinizing hormone-triggered target gene expression during ovulation.	CITED4 CREBBP	2.39e-05	4	70	2	24878634
Pubmed	CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation.	CEBPB CREBBP	2.39e-05	4	70	2	12857754
Pubmed	Nuclear protein CBP is a coactivator for the transcription factor CREB.	GLI3 CREBBP	2.39e-05	4	70	2	7913207
Pubmed	Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pre-gastrulation to early somite stages.	SOX1 SOX3	2.39e-05	4	70	2	10446282
Pubmed	Interactive Organization of the Circadian Core Regulators PER2, BMAL1, CLOCK and PML.	PER2 PML	2.39e-05	4	70	2	27383066
Pubmed	A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts.	CEBPB CREBBP	2.39e-05	4	70	2	16303757
Pubmed	Evaluation of mRNA Expressions of TOX and NR4As in CD8+ T cells in Acute Leukemia.	TOX NR4A1	2.39e-05	4	70	2	37961948
Pubmed	Hes6 controls cell proliferation via interaction with cAMP-response element-binding protein-binding protein in the promyelocytic leukemia nuclear body.	CREBBP PML	2.39e-05	4	70	2	18160400
Pubmed	PML regulates PER2 nuclear localization and circadian function.	PER2 PML	2.39e-05	4	70	2	22274616
Pubmed	Proteomic analysis of steady-state nuclear hormone receptor coactivator complexes.	IRF2BP2 NFATC3 SRRM2 CREBBP	2.69e-05	85	70	4	16051665
Pubmed	Senescence is a developmental mechanism that contributes to embryonic growth and patterning.	CEBPB GLI3 PML	3.05e-05	30	70	3	24238961
Pubmed	Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome.	ID4 RUNX1	3.98e-05	5	70	2	27667480
Pubmed	Promyelocytic leukaemia-immunoreactive neuronal intranuclear rodlets in the human brain.	CREBBP PML	3.98e-05	5	70	2	17239008
Pubmed	Role of the hepatocyte nuclear factor-1beta (HNF-1beta) C-terminal domain in Pkhd1 (ARPKD) gene transcription and renal cystogenesis.	HNF1A CREBBP	3.98e-05	5	70	2	15647252
Pubmed	MFH-1, a new member of the fork head domain family, is expressed in developing mesenchyme.	HNF1A FOXC2	3.98e-05	5	70	2	8325367
Pubmed	Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin.	CITED4 CREBBP	3.98e-05	5	70	2	15572674
Pubmed	The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells.	NR4A1 RUNX1	3.98e-05	5	70	2	21468021
Pubmed	Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9.	CREB3L4 CREBBP	3.98e-05	5	70	2	12732631
Pubmed	Dynamic regulation of p53 subnuclear localization and senescence by MORC3.	CREBBP PML	3.98e-05	5	70	2	17332504
Pubmed	The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors.	CITED4 CREBBP	3.98e-05	5	70	2	10722728
Pubmed	Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.	RUNX1 PML	3.98e-05	5	70	2	10882117
Pubmed	Chromosomal localization in man and rat of the genes encoding the liver-enriched transcription factors C/EBP, DBP, and HNF1/LFB-1 (CEBP, DBP, and transcription factor 1, TCF1, respectively) and of the hepatocyte growth factor/scatter factor gene (HGF).	HNF1A CEBPB	3.98e-05	5	70	2	1535333
Pubmed	Promyelocytic Leukemia Protein Isoform II Promotes Transcription Factor Recruitment To Activate Interferon Beta and Interferon-Responsive Gene Expression.	CREBBP PML	3.98e-05	5	70	2	25733689
Pubmed	Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.	RUNX1 PML	3.98e-05	5	70	2	30755814
Pubmed	A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes.	SOX1 SOX3	3.98e-05	5	70	2	2374589
Pubmed	CREB4, a transmembrane bZip transcription factor and potential new substrate for regulation and cleavage by S1P.	CREB3L3 CREB3L4	3.98e-05	5	70	2	16236796
Pubmed	The AERO system: a 3D-like approach for recording gene expression patterns in the whole mouse embryo.	ZNF219 GLI3 DLX2 RUNX1 FOXC2	4.30e-05	191	70	5	24146773
Pubmed	Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia.	SOX1 HNF1A GLI3 DLX2 PRDM16 FOXC2	5.58e-05	331	70	6	20634891
Pubmed	The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression.	AFF1 RUNX1	5.96e-05	6	70	2	16386788
Pubmed	[Role of molecular screening for common fusion genes in the diagnosis and classification of leukemia].	RUNX1 PML	5.96e-05	6	70	2	15968309
Pubmed	Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins.	HNF1A CREBBP	5.96e-05	6	70	2	10777539
Pubmed	Regulation of T cell activation by HIV-1 accessory proteins: Vpr acts via distinct mechanisms to cooperate with Nef in NFAT-directed gene expression and to promote transactivation by CREB.	NFATC3 CREBBP	5.96e-05	6	70	2	12788643
Pubmed	New insights into the function and regulation of vitamin D target proteins.	CEBPB CREBBP	5.96e-05	6	70	2	17257825
Pubmed	A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.	CREBBP PML	5.96e-05	6	70	2	10610177
Pubmed	SUMO-1-dependent allosteric regulation of thymine DNA glycosylase alters subnuclear localization and CBP/p300 recruitment.	CREBBP PML	5.96e-05	6	70	2	17060459
Pubmed	Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS.	IRF2BP2 PHLDB1 ATXN2 SRRM2	6.89e-05	108	70	4	19531213
Pubmed	Interplay of SOX and POU factors in regulation of the Nestin gene in neural primordial cells.	SOX1 SOX3	8.33e-05	7	70	2	15456859
Pubmed	FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction.	CREBBP PML	8.33e-05	7	70	2	16154098
Pubmed	Pairing SOX off: with partners in the regulation of embryonic development.	SOX1 SOX3	8.33e-05	7	70	2	10729834
Pubmed	Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein.	RUNX1 CREBBP	8.33e-05	7	70	2	11742995
Pubmed	SUMO interaction motifs in Sizn1 are required for promyelocytic leukemia protein nuclear body localization and for transcriptional activation.	CREBBP PML	8.33e-05	7	70	2	19416967
Pubmed	Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions.	RUNX1 CREBBP	8.33e-05	7	70	2	7774816
Pubmed	Evidence that the SRY protein is encoded by a single exon on the human Y chromosome.	SOX1 SOX3	8.33e-05	7	70	2	8244390
Pubmed	Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappaB signals via repression of peroxisome proliferator-activated receptor gamma.	CEBPB CREBBP	8.33e-05	7	70	2	20829347
Pubmed	A role for Id2 in regulating photic entrainment of the mammalian circadian system.	PER2 ID4	8.33e-05	7	70	2	19217292
Pubmed	Enhancer-mediated control of macrophage-specific arginase I expression.	CEBPB CREBBP	8.33e-05	7	70	2	15187136
Pubmed	Region-specific Etv2 ablation revealed the critical origin of hemogenic capacity from Hox6-positive caudal-lateral primitive mesoderm.	SOX1 RUNX1	1.11e-04	8	70	2	23438573
Pubmed	Cell cycle regulator E2F4 is essential for the development of the ventral telencephalon.	GLI3 DLX2	1.11e-04	8	70	2	17537963
Pubmed	Transcriptional activation of known and novel apoptotic pathways by Nur77 orphan steroid receptor.	CHCHD10 NR4A1	1.11e-04	8	70	2	14657025
Interaction	TOP3B interactions	HIVEP3 PHLDB1 CEBPB PER2 ADAMTS7 ATXN2 BICRA INTS1 PLEKHA4 NINL SAC3D1 DLX2 ANKLE1 KIFC3 MLXIP MBD6 RGL2 PRDM16 CIT ZNF687	4.42e-08	1470	68	20	int:TOP3B
Interaction	SMARCA4 interactions	HNF1A CEBPB BICRA GLI3 PLEKHA4 NR4A1 RUNX1 SRRM2 CIT CREBBP PML	3.86e-07	462	68	11	int:SMARCA4
Interaction	GATAD2A interactions	ZNF219 CEBPB PLEKHA4 RUNX1 PRDM16 CREBBP ZNF687 PML	8.57e-07	224	68	8	int:GATAD2A
Interaction	YWHAB interactions	HNF1A PHLDB1 MAP7D1 LRFN4 CEBPB NFATC3 KIF26B PLEKHA4 NINL CNTLN MLXIP ATAT1 PARD3 SRRM2 RGL2	1.09e-06	1014	68	15	int:YWHAB
Interaction	SMAD3 interactions	MAGI2 CEBPB GLI3 PLEKHA4 NR4A1 RUNX1 PARD3 PRDM16 CREBBP PML	2.40e-06	447	68	10	int:SMAD3
Interaction	DDX5 interactions	CEBPB ATXN2 NACA PLEKHA4 NR4A1 RUNX1 MBD6 SRRM2 CREB3L4 CIT CREBBP	2.89e-06	568	68	11	int:DDX5
Interaction	YWHAG interactions	CRACD HNF1A PHLDB1 MAP7D1 LRFN4 CEBPB NFATC3 KIF26B PLEKHA4 NINL CNTLN MLXIP ATAT1 PARD3 SRRM2 RGL2	2.92e-06	1248	68	16	int:YWHAG
Interaction	YWHAE interactions	DCAF1 CRACD HNF1A PHLDB1 MAP7D1 CEBPB PER2 KIF26B PLEKHA4 CNTLN MLXIP MBD6 ATAT1 PARD3 SRRM2 RGL2	3.17e-06	1256	68	16	int:YWHAE
Interaction	HDAC2 interactions	DCAF1 IRF2BP2 ZNF219 CEBPB PLEKHA4 RUNX1 SRRM2 PRDM16 CIT CREBBP ZNF687 PML FOXC2	5.39e-06	865	68	13	int:HDAC2
Interaction	HIPK1 interactions	RUNX1 CIT CREBBP PML	8.92e-06	39	68	4	int:HIPK1
Interaction	NONO interactions	CEBPB PER2 PLEKHA4 NINL NR4A1 RUNX1 SRRM2 CIT CREBBP PML	1.46e-05	549	68	10	int:NONO
Interaction	HDAC1 interactions	DCAF1 MAP7D1 ZNF219 CEBPB GLI3 PLEKHA4 AFF1 NR4A1 RUNX1 PRDM16 CIT CREBBP ZNF687 PML	1.61e-05	1108	68	14	int:HDAC1
Interaction	GATAD2B interactions	ZNF219 CEBPB PLEKHA4 RUNX1 PRDM16 CIT PML	1.86e-05	245	68	7	int:GATAD2B
Interaction	DDX41 interactions	CEBPB PLEKHA4 RUNX1 SRRM2 CREB3L4 CIT	2.05e-05	166	68	6	int:DDX41
Interaction	KDM3B interactions	CEBPB NACA PLEKHA4 CREBBP PML	2.21e-05	100	68	5	int:KDM3B
Interaction	YWHAZ interactions	CRACD HNF1A PHLDB1 MAP7D1 CEBPB EFNB3 PER2 NFATC3 KIF26B PLEKHA4 NR4A1 MLXIP ATAT1 PARD3 PML	2.64e-05	1319	68	15	int:YWHAZ
Interaction	CIITA interactions	CITED4 NINL CREBBP PML	3.55e-05	55	68	4	int:CIITA
Interaction	SIN3A interactions	IRF2BP2 CEBPB PER2 PLEKHA4 RUNX1 CIT CREBBP PML	4.09e-05	380	68	8	int:SIN3A
Interaction	SMARCC1 interactions	CEBPB BICRA PLEKHA4 NR4A1 RUNX1 SRRM2 CIT CREBBP	4.40e-05	384	68	8	int:SMARCC1
Interaction	PHIP interactions	GLI3 PLEKHA4 SRRM2 PRDM16 CIT PML	5.35e-05	197	68	6	int:PHIP
Interaction	RAB1C interactions	PLEKHA4 LMTK3 CIT	5.40e-05	22	68	3	int:RAB1C
Interaction	MBD3 interactions	MAGEA2 ZNF219 CEBPB PLEKHA4 RUNX1 SRRM2 PRDM16	6.06e-05	295	68	7	int:MBD3
Interaction	DDX3X interactions	CEBPB ATXN2 PLEKHA4 SAC3D1 NR4A1 RUNX1 MBD6 SRRM2 CREBBP PML	6.20e-05	651	68	10	int:DDX3X
Interaction	BAZ1B interactions	CEBPB PLEKHA4 LMTK3 SRRM2 PRDM16 CIT	6.49e-05	204	68	6	int:BAZ1B
Interaction	RUNX2 interactions	HIVEP3 CEBPB RUNX1 CREBBP PML	6.71e-05	126	68	5	int:RUNX2
Interaction	ACOT8 interactions	PLEKHA4 PRDM16 CIT PML	6.87e-05	65	68	4	int:ACOT8
Interaction	YWHAH interactions	PHLDB1 MAP7D1 CEBPB NFATC3 KIF26B PLEKHA4 NINL MLXIP ATAT1 PARD3 SRRM2 RGL2 CREBBP	6.88e-05	1102	68	13	int:YWHAH
Interaction	RUNX1T1 interactions	CEBPB ID4 KIFC3 RUNX1 PRDM16	6.97e-05	127	68	5	int:RUNX1T1
Interaction	SPI1 interactions	CEBPB RUNX1 CREBBP PML	7.74e-05	67	68	4	int:SPI1
Interaction	KHSRP interactions	CEBPB PLEKHA4 NINL NR4A1 RUNX1 MBD6 CIT	7.94e-05	308	68	7	int:KHSRP
Interaction	FOS interactions	CABP1 HNF1A NFATC3 NACA RUNX1 CREBBP PML	8.61e-05	312	68	7	int:FOS
Interaction	HDAC3 interactions	DCAF1 MAGEA2 IRF2BP2 NINL RUNX1 CREBBP PML	8.78e-05	313	68	7	int:HDAC3
Interaction	KMT2A interactions	PER2 PLEKHA4 AFF1 RUNX1 CIT CREBBP PML	8.96e-05	314	68	7	int:KMT2A
Interaction	DDX17 interactions	CEBPB ATXN2 PLEKHA4 RUNX1 MBD6 CREB3L4 CIT CREBBP	9.10e-05	426	68	8	int:DDX17
Interaction	MTA2 interactions	ZNF219 CEBPB PLEKHA4 NR4A1 RUNX1 SRRM2 PRDM16 CIT	1.05e-04	435	68	8	int:MTA2
Interaction	ZNF326 interactions	CEBPB PLEKHA4 NR4A1 RUNX1 LMTK3 CIT	1.09e-04	224	68	6	int:ZNF326
Interaction	FIP1L1 interactions	CEBPB PLEKHA4 RUNX1 SRRM2 CIT PML	1.11e-04	225	68	6	int:FIP1L1
Interaction	TCF12 interactions	IRF2BP2 ID4 RUNX1 CREBBP PML	1.43e-04	148	68	5	int:TCF12
Interaction	NAP1L1 interactions	CEBPB PLEKHA4 NINL PRDM16 CIT CREBBP PML	1.60e-04	345	68	7	int:NAP1L1
Interaction	IRF2BP1 interactions	IRF2BP2 CEBPB PLEKHA4 PML	1.62e-04	81	68	4	int:IRF2BP1
Interaction	SMARCA2 interactions	CEBPB BICRA PLEKHA4 NR4A1 SRRM2 CIT CREBBP	1.63e-04	346	68	7	int:SMARCA2
Interaction	RBM39 interactions	IRF2BP2 MAP7D1 CITED4 CEBPB ATXN2 NACA PLEKHA4 NINL RUNX1 SRRM2 PRDM16 CIT	1.71e-04	1042	68	12	int:RBM39
Interaction	CDC16 interactions	TROAP PLEKHA4 RUNX1 CREBBP ZNF687 PML	1.81e-04	246	68	6	int:CDC16
Interaction	SMARCC2 interactions	CEBPB BICRA PLEKHA4 NR4A1 RUNX1 CIT CREBBP	1.85e-04	353	68	7	int:SMARCC2
Interaction	RAG1 interactions	DCAF1 RUNX1 CIT	1.86e-04	33	68	3	int:RAG1
Interaction	INTS5 interactions	INTS1 PLEKHA4 CIT ZNF687 PML	1.95e-04	158	68	5	int:INTS5
Interaction	INTS9 interactions	INTS1 PLEKHA4 RUNX1 CIT	1.95e-04	85	68	4	int:INTS9
Interaction	ANAPC7 interactions	PLEKHA4 CREB3L4 CIT CREBBP PML	2.19e-04	162	68	5	int:ANAPC7
Interaction	NCOR1 interactions	IRF2BP2 CEBPB PLEKHA4 NINL RUNX1 CREBBP PML	2.19e-04	363	68	7	int:NCOR1
Interaction	MYL6 interactions	CEBPB PLEKHA4 NINL PARD3 SRRM2 CIT	2.20e-04	255	68	6	int:MYL6
Interaction	PLEKHA6 interactions	PLEKHA4 PARD3 CIT	2.23e-04	35	68	3	int:PLEKHA6
Interaction	BAG2 interactions	IRF2BP2 CEBPB PLEKHA4 NINL GREB1 SRRM2 CIT CREBBP PML	2.33e-04	622	68	9	int:BAG2
Interaction	KHDRBS1 interactions	CEBPB ATXN2 PLEKHA4 CREB3L3 PRDM16 CIT CREBBP	2.58e-04	373	68	7	int:KHDRBS1
Interaction	EIF3E interactions	CEBPB PER2 PLEKHA4 PRDM16 CIT PML	2.59e-04	263	68	6	int:EIF3E
Interaction	NCOR2 interactions	IRF2BP2 CEBPB NR4A1 RUNX1 CREBBP PML	2.65e-04	264	68	6	int:NCOR2
Interaction	TAL1 interactions	IRF2BP2 ID4 RUNX1 CREBBP	2.76e-04	93	68	4	int:TAL1
Interaction	DHX15 interactions	CEBPB ATXN2 PLEKHA4 NR4A1 RUNX1 SRRM2 CIT PML	2.79e-04	502	68	8	int:DHX15
Interaction	NUP93 interactions	CEBPB PLEKHA4 LMTK3 PRDM16 CIT CREBBP	2.93e-04	269	68	6	int:NUP93
Interaction	RORA interactions	DCAF1 CEBPB CREBBP	3.08e-04	39	68	3	int:RORA
Interaction	INTS1 interactions	INTS1 PLEKHA4 MBD6 CIT ZNF687	3.12e-04	175	68	5	int:INTS1
Interaction	SMAD2 interactions	GLI3 PLEKHA4 RUNX1 PARD3 PRDM16 CREBBP PML	3.13e-04	385	68	7	int:SMAD2
Interaction	MKRN2 interactions	MAGI2 ATXN2 GLI3 PLEKHA4 ID4 DLX2 PARD3	3.13e-04	385	68	7	int:MKRN2
Interaction	LMO7 interactions	NACA NINL PARD3 CIT PML	3.29e-04	177	68	5	int:LMO7
Interaction	CSNK2A1 interactions	ATXN2 NACA PLEKHA4 CREB3L3 NR4A1 SRRM2 PRDM16 CIT CREBBP ZNF687 PML	3.31e-04	956	68	11	int:CSNK2A1
Interaction	SQOR interactions	CEBPB PLEKHA4 CIT PML	3.37e-04	98	68	4	int:SQOR
Interaction	POLD3 interactions	CEBPB PLEKHA4 RUNX1 PML	3.37e-04	98	68	4	int:POLD3
Interaction	KPNA2 interactions	CEBPB PLEKHA4 CREB3L3 MBD6 RGL2 PRDM16 CIT CREBBP	3.49e-04	519	68	8	int:KPNA2
Interaction	PIAS2 interactions	PLEKHA4 KIFC3 NR4A1 CREBBP PML	3.56e-04	180	68	5	int:PIAS2
Interaction	TRIP13 interactions	TNFRSF9 VENTX PLEKHA4 LMTK3 PARD3 CIT	3.70e-04	281	68	6	int:TRIP13
Interaction	PPP2R1A interactions	DCAF1 ZNF219 CEBPB NACA INTS1 PLEKHA4 CIT PML FOXC2	3.81e-04	665	68	9	int:PPP2R1A
Interaction	SMARCD2 interactions	CEBPB BICRA PLEKHA4 NR4A1 CIT	3.84e-04	183	68	5	int:SMARCD2
Interaction	RASSF7 interactions	CEBPB NINL PARD3	3.84e-04	42	68	3	int:RASSF7
Interaction	SMARCE1 interactions	CEBPB BICRA PLEKHA4 KIFC3 NR4A1 RUNX1	4.13e-04	287	68	6	int:SMARCE1
Interaction	CBFB interactions	CEBPB PLEKHA4 RUNX1 PML	4.23e-04	104	68	4	int:CBFB
Interaction	RECQL interactions	CEBPB NACA PLEKHA4 RUNX1 CIT PML	4.29e-04	289	68	6	int:RECQL
Interaction	HNRNPR interactions	CEBPB ATXN2 PLEKHA4 NR4A1 RUNX1 MBD6 CIT PML	4.33e-04	536	68	8	int:HNRNPR
Interaction	PELP1 interactions	PLEKHA4 NR4A1 CIT CREBBP PML	4.45e-04	189	68	5	int:PELP1
Interaction	PRPF3 interactions	CEBPB PLEKHA4 NINL SRRM2 CIT PML	4.45e-04	291	68	6	int:PRPF3
Interaction	HCFC1 interactions	CEBPB PLEKHA4 RUNX1 MBD6 CIT PML	4.61e-04	293	68	6	int:HCFC1
Interaction	SMCHD1 interactions	CEBPB PER2 PLEKHA4 CIT PML	4.66e-04	191	68	5	int:SMCHD1
Interaction	CBFA2T2 interactions	IRF2BP2 KIFC3 RUNX1	4.71e-04	45	68	3	int:CBFA2T2
Interaction	MED26 interactions	CEBPB AFF1 RUNX1 PML	4.71e-04	107	68	4	int:MED26
Interaction	SSRP1 interactions	HNF1A CEBPB INTS1 PLEKHA4 LMTK3 SRRM2 PRDM16 CIT ZNF687	4.72e-04	685	68	9	int:SSRP1
Interaction	AKAP8 interactions	CEBPB PLEKHA4 NR4A1 PRDM16 FOXC2	4.89e-04	193	68	5	int:AKAP8
Interaction	SMARCA5 interactions	HNF1A CEBPB PLEKHA4 LMTK3 PRDM16 CIT FOXC2	4.91e-04	415	68	7	int:SMARCA5
Interaction	SBNO2 interactions	CEBPB PML	4.96e-04	10	68	2	int:SBNO2
Interaction	LUZP1 interactions	CEBPB PLEKHA4 NINL CIT PML	5.01e-04	194	68	5	int:LUZP1
Interaction	CTNNB1 interactions	SOX1 MAGI2 HNF1A PLEKHA4 NR4A1 RUNX1 PARD3 SRRM2 CIT CREBBP PML	5.23e-04	1009	68	11	int:CTNNB1
Interaction	INTS6 interactions	INTS1 PLEKHA4 ZNF687 PML	5.23e-04	110	68	4	int:INTS6
Interaction	PPP1CA interactions	IRF2BP2 CEBPB GLI3 NACA PLEKHA4 NINL PARD3 CIT CREBBP	5.29e-04	696	68	9	int:PPP1CA
Interaction	HNRNPH3 interactions	CEBPB PER2 PLEKHA4 SRRM2 CIT PML	5.32e-04	301	68	6	int:HNRNPH3
Interaction	CLIP4 interactions	MAP7D1 KIFC3 RUNX1	5.36e-04	47	68	3	int:CLIP4
Interaction	RGPD3 interactions	PLEKHA4 CIT PML	5.36e-04	47	68	3	int:RGPD3
Interaction	CUX1 interactions	TNFRSF9 CEBPB PLEKHA4 CIT CREBBP	5.62e-04	199	68	5	int:CUX1
Interaction	SAP18 interactions	CEBPB GLI3 NINL SRRM2 CIT PML	5.70e-04	305	68	6	int:SAP18
Interaction	PBDC1 interactions	CEBPB NACA PLEKHA4	5.70e-04	48	68	3	int:PBDC1
Interaction	RO60 interactions	ATXN2 NACA PLEKHA4 CIT CREBBP	5.75e-04	200	68	5	int:RO60
Interaction	P4HB interactions	LRFN4 CEBPB PER2 PLEKHA4 NR4A1 CIT PML	5.81e-04	427	68	7	int:P4HB
Interaction	ZNF687 interactions	INTS1 CIT ZNF687 PML	6.18e-04	115	68	4	int:ZNF687
Interaction	LCP1 interactions	CEBPB ATXN2 PLEKHA4 RUNX1	6.18e-04	115	68	4	int:LCP1
GeneFamily	Basic leucine zipper proteins	CEBPB CREB3L3 CREB3L4	2.62e-04	49	46	3	506
GeneFamily	SRY-boxes	SOX1 SOX3	1.05e-03	19	46	2	757
Coexpression	GSE14308_TH17_VS_NAIVE_CD4_TCELL_DN	DCAF1 HIVEP3 TMEM132E AFF1 NR4A1 RGL2 ZNF687	1.05e-06	199	70	7	M3384
Coexpression	GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP	DCAF1 CHCHD10 MAP7D1 CITED4 ZNF219 EFNB3 ADAMTS7 RIN2 PLEKHA4 SAC3D1 KIFC3 NR4A1 PML	9.74e-06	1151	70	13	M1103
Coexpression	GSE21670_IL6_VS_TGFB_AND_IL6_TREATED_STAT3_KO_CD4_TCELL_DN	TOX ADAMTS7 KIF26B NR4A1 RGL2 PML	1.55e-05	199	70	6	M7451
Coexpression	GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP	DCAF1 CHCHD10 MAP7D1 CITED4 ZNF219 EFNB3 ADAMTS7 RIN2 PLEKHA4 SAC3D1 KIFC3 NR4A1 PML	1.90e-05	1226	70	13	MM979
Coexpression	GRESHOCK_CANCER_COPY_NUMBER_UP	HNF1A NACA AFF1 RUNX1 PRDM16 CREBBP PML	2.49e-05	323	70	7	M9150
Coexpression	KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN	PHLDB1 TOX KIF26B RIN2 AFF1 DLX2 SRRM2	3.27e-05	337	70	7	M13206
Coexpression	MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_30	HNF1A NACA	6.99e-05	5	70	2	M14194
Coexpression	CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP	CRACD PRR36 ATXN2 NACA SRRM2 CREB3L4 RGL2	7.56e-05	385	70	7	M2840
Coexpression	BURTON_ADIPOGENESIS_1	CEBPB DLX2 FOXC2	7.77e-05	31	70	3	M1612
Coexpression	BURTON_ADIPOGENESIS_1	CEBPB DLX2 FOXC2	7.77e-05	31	70	3	MM1191
CoexpressionAtlas	FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_1000	HIVEP3 FNDC1 CHCHD10 TOX RTL1 KIF26B NPTXR ID4 DLX2 GREB1 RUNX1 LMTK3 PRDM16 EBF4	2.68e-06	967	70	14	Facebase_RNAseq_e9.5_Maxillary Arch_1000
CoexpressionAtlas	FacebaseRNAseq_e9.5_Olfactory Placode_top-relative-expression-ranked_2500_k-means-cluster#4	TOX PRR36 ADAMTS7 RTL1 NPTXR NINL ID4 DLX2 LMTK3 PRDM16 EBF4	1.35e-05	683	70	11	Facebase_RNAseq_e9.5_Olfactory Placode_2500_K4
CoexpressionAtlas	FacebaseRNAseq_e8.5_Paraxial Mesoderm_top-relative-expression-ranked_1000	HIVEP3 FNDC1 TOX PRR36 RTL1 KIF26B NPTXR PLEKHA4 ID4 CNTLN RUNX1 PRDM16 EBF4	1.42e-05	967	70	13	Facebase_RNAseq_e8.5_Paraxial Mesoderm_1000
CoexpressionAtlas	FacebaseRNAseq_e9.5_Facial Mesenchyne_top-relative-expression-ranked_1000	HIVEP3 FNDC1 CHCHD10 TOX RTL1 KIF26B NPTXR ID4 GREB1 CNTLN RUNX1 PRDM16 EBF4	1.44e-05	968	70	13	Facebase_RNAseq_e9.5_Facial Mesenchyne_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Mandibular Arch_top-relative-expression-ranked_2500_k-means-cluster#5	TOX PRR36 ADAMTS7 RTL1 NPTXR ID4 DLX2 ANKLE1 LMTK3 PRDM16 EBF4	1.45e-05	688	70	11	Facebase_RNAseq_e10.5_Mandibular Arch_2500_K5
CoexpressionAtlas	FacebaseRNAseq_e8.5_Paraxial Mesoderm_top-relative-expression-ranked_1000_k-means-cluster#4	TOX PRR36 RTL1 NPTXR ID4 PRDM16 EBF4	1.70e-05	247	70	7	Facebase_RNAseq_e8.5_Paraxial Mesoderm_1000_K4
CoexpressionAtlas	FacebaseRNAseq_e10.5_Olfactory Pit_top-relative-expression-ranked_1000	HIVEP3 CRACD FNDC1 CHCHD10 ZNF219 TOX PRR36 KIF26B NINL ID4 RUNX1 PRDM16 EBF4	1.71e-05	984	70	13	Facebase_RNAseq_e10.5_Olfactory Pit_1000
CoexpressionAtlas	FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_1000_k-means-cluster#2	TOX PRR36 RTL1 NPTXR ID4 PRDM16 EBF4	1.79e-05	249	70	7	Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_1000_K2
CoexpressionAtlas	FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_2500_k-means-cluster#5	TOX PRR36 ADAMTS7 RTL1 NPTXR GLI3 NINL ID4 LMTK3 PRDM16 EBF4	2.57e-05	732	70	11	Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_2500_K5
CoexpressionAtlas	FacebaseRNAseq_e10.5_Medial Nasal Eminence_top-relative-expression-ranked_2500_k-means-cluster#1	TOX PRR36 ADAMTS7 RTL1 NPTXR NINL ID4 LMTK3 PRDM16 EBF4	3.16e-05	614	70	10	Facebase_RNAseq_e10.5_Medial Nasal Eminence_2500_K1
CoexpressionAtlas	FacebaseRNAseq_e10.5_Olfactory Pit_top-relative-expression-ranked_1000_k-means-cluster#2	CRACD TOX PRR36 NINL ID4 PRDM16 EBF4	3.71e-05	279	70	7	Facebase_RNAseq_e10.5_Olfactory Pit_1000_K2
CoexpressionAtlas	FacebaseRNAseq_e10.5_Olfactory Pit_top-relative-expression-ranked_2500_k-means-cluster#2	CRACD TOX PRR36 ADAMTS7 RTL1 NPTXR ID4 LMTK3 PRDM16 EBF4	5.73e-05	659	70	10	Facebase_RNAseq_e10.5_Olfactory Pit_2500_K2
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_2500_k-means-cluster#1	PRR36 RTL1 NPTXR NINL RUNX1 PRDM16 EBF4	6.64e-05	306	70	7	Facebase_RNAseq_e10.5_Maxillary Arch_2500_K1
CoexpressionAtlas	FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_1000	HIVEP3 FNDC1 TOX RTL1 KIF26B NPTXR PLEKHA4 ID4 CNTLN RUNX1 PRDM16 EBF4	6.89e-05	967	70	12	Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_1000
CoexpressionAtlas	FacebaseRNAseq_e9.5_Olfactory Placode_top-relative-expression-ranked_1000	HIVEP3 FNDC1 CHCHD10 ZNF219 TOX PRR36 KIF26B NINL DLX2 GREB1 RUNX1 EBF4	7.31e-05	973	70	12	Facebase_RNAseq_e9.5_Olfactory Placode_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Mandibular Arch_top-relative-expression-ranked_1000	HIVEP3 FNDC1 TOX KIF26B PLEKHA4 ID4 C11orf87 DLX2 RUNX1 PRDM16 CREBBP EBF4	7.67e-05	978	70	12	Facebase_RNAseq_e10.5_Mandibular Arch_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_1000	TOX PRR36 RTL1 KIF26B GLI3 ID4 C11orf87 DLX2 CNTLN PRDM16 CIT EBF4	8.06e-05	983	70	12	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_1000	HIVEP3 FNDC1 PRR36 ADAMTS7 RTL1 NPTXR NINL ID4 DLX2 CNTLN PRDM16 CIT	8.29e-05	986	70	12	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_1000	DCAF1 MAP7D1 TOX PRR36 KIF26B GLI3 NINL DLX2 CNTLN RGL2 PRDM16 CIT	8.54e-05	989	70	12	Facebase_RNAseq_e10.5_Maxillary Arch_1000
CoexpressionAtlas	FacebaseRNAseq_e9.5_Facial Mesenchyne_top-relative-expression-ranked_1000_k-means-cluster#4	TOX RTL1 NPTXR ID4 PRDM16 EBF4	9.39e-05	223	70	6	Facebase_RNAseq_e9.5_Facial Mesenchyne_1000_K4
CoexpressionAtlas	FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_1000_k-means-cluster#4	TOX RTL1 NPTXR ID4 PRDM16 EBF4	1.17e-04	232	70	6	Facebase_RNAseq_e9.5_Maxillary Arch_1000_K4
CoexpressionAtlas	FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_1000_k-means-cluster#1	TOX RTL1 NPTXR ID4 PRDM16 EBF4	1.19e-04	233	70	6	Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_1000_K1
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_500_k-means-cluster#2	TOX PRR36 DLX2 PRDM16	1.35e-04	79	70	4	Facebase_RNAseq_e10.5_Maxillary Arch_500_K2
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_2500_k-means-cluster#3	TOX PRR36 ADAMTS7 RTL1 NPTXR NINL ID4 LMTK3 PRDM16 CIT EBF4	1.53e-04	893	70	11	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_2500_K3
CoexpressionAtlas	FacebaseRNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#2	TOX PRR36 ADAMTS7 RTL1 NPTXR ID4 ANKLE1 LMTK3 PRDM16 EBF4	1.61e-04	747	70	10	Facebase_RNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_2500_K2
CoexpressionAtlas	FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_1000_k-means-cluster#2	TOX PRR36 GLI3 NINL ID4 EBF4	1.68e-04	248	70	6	Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_1000_K2
CoexpressionAtlas	FacebaseRNAseq_e9.5_Mandibular Arch_top-relative-expression-ranked_1000_k-means-cluster#3	DCAF1 CHCHD10 DLX2 LMTK3 MBD6 RGL2 ZNF513	1.79e-04	359	70	7	Facebase_RNAseq_e9.5_Mandibular Arch_1000_K3
CoexpressionAtlas	FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_500	CHCHD10 TOX KIF26B DLX2 GREB1 RUNX1 LMTK3 EBF4	1.86e-04	483	70	8	Facebase_RNAseq_e9.5_Maxillary Arch_500
CoexpressionAtlas	dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_k-means-cluster#3_top-relative-expression-ranked_1000	MAGI2 IRF2BP2 RIN2 AFF1 CNTLN RUNX1	2.65e-04	270	70	6	gudmap_dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_k3_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_1000_k-means-cluster#2	MAP7D1 PRR36 NINL DLX2 PRDM16	2.67e-04	173	70	5	Facebase_RNAseq_e10.5_Maxillary Arch_1000_K2
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ Genital tubercle_emap-6706_top-relative-expression-ranked_500	MAGI2 IRF2BP2 TOX KIF26B GLI3 DLX2 RUNX1	2.96e-04	390	70	7	gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle_500
CoexpressionAtlas	FacebaseRNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#5	TOX PRR36 ADAMTS7 RTL1 NPTXR ID4 LMTK3 PRDM16 EBF4	3.00e-04	658	70	9	Facebase_RNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_2500_K5
CoexpressionAtlas	FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_1000	HIVEP3 FNDC1 TOX PRR36 RTL1 KIF26B NPTXR ID4 RUNX1 PRDM16 EBF4	3.18e-04	972	70	11	Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_1000
CoexpressionAtlas	FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_1000	HIVEP3 FNDC1 TOX PRR36 KIF26B GLI3 NINL ID4 GREB1 RUNX1 EBF4	3.29e-04	976	70	11	Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_1000
CoexpressionAtlas	FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#4	TOX PRR36 ADAMTS7 RTL1 NPTXR ID4 LMTK3 PRDM16 EBF4	5.83e-04	721	70	9	Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_2500_K4
CoexpressionAtlas	FacebaseRNAseq_e9.5_Facial Mesenchyne_top-relative-expression-ranked_2500_k-means-cluster#5	TOX PRR36 ADAMTS7 RTL1 NPTXR ID4 LMTK3 PRDM16 EBF4	5.89e-04	722	70	9	Facebase_RNAseq_e9.5_Facial Mesenchyne_2500_K5
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_2500_k-means-cluster#3	PRR36 ADAMTS7 RTL1 NPTXR DLX2 LMTK3 PRDM16	6.68e-04	447	70	7	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_2500_K3
CoexpressionAtlas	FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#5	TOX PRR36 ADAMTS7 RTL1 NPTXR ID4 LMTK3 PRDM16 EBF4	7.22e-04	743	70	9	Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_2500_K5
CoexpressionAtlas	Ectoderm Differentiated Cells_vs_Endoderm Differentiated Cells-Confounder_removed-fold2.0_adjp0.05	SOX1 PHLDB1 ZNF219 EFNB3 PRR36 ADAMTS7 GLI3 PLEKHA4 ID4 GREB1 ATAT1	7.39e-04	1075	70	11	PCBC_ratio_ECTO_vs_DE_cfr-2X-p05
CoexpressionAtlas	FacebaseRNAseq_e10.5_Medial Nasal Eminence_top-relative-expression-ranked_1000_k-means-cluster#5	PRR36 RTL1 NPTXR NINL	7.54e-04	124	70	4	Facebase_RNAseq_e10.5_Medial Nasal Eminence_1000_K5
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_1000_k-means-cluster#3	PRR36 ADAMTS7 RTL1 NPTXR DLX2 PRDM16	8.80e-04	339	70	6	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_1000_K3
CoexpressionAtlas	alpha beta T cells, T.DP69+.Th, 4+ 8+ TCRlo/int 69+, Thymus, avg-3	HIVEP3 TOX NR4A1	8.84e-04	57	70	3	GSM399394_100
CoexpressionAtlas	DevelopingKidney_e15.5_Pelvic Mesenchyme_emap-8241_k-means-cluster#2_top-relative-expression-ranked_200	KIF26B FOXC2	9.50e-04	14	70	2	gudmap_developingKidney_e15.5_Pelvic Mesenchyme_200_k2
CoexpressionAtlas	MESO-15 amniotic fluid MSC_vs_MESO-15 blastocyst-Confounder_removed-fold2.0_adjp0.05	DCAF1 ZNF219 CEBPB EFNB3 TOX PRR36 GLI3 ID4 GREB1 NR4A1 PARD3 CREB3L4 CIT	9.76e-04	1479	70	13	PCBC_ratio_MESO-15 amniotic fluid MSC_vs_MESO-15 blastocyst_cfr-2X-p05
CoexpressionAtlas	FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_500_k-means-cluster#4	CHCHD10 DLX2 RUNX1 LMTK3	9.80e-04	133	70	4	Facebase_RNAseq_e9.5_Maxillary Arch_500_K4
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_500	CRACD ZNF219 PRR36 NINL ID4 DLX2 PRDM16	1.04e-03	482	70	7	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_500
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_1000_k-means-cluster#1	DCAF1 MAP7D1 ZNF219 DLX2 RGL2	1.09e-03	236	70	5	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_1000_K1
CoexpressionAtlas	FacebaseRNAseq_e10.5_Maxillary Arch_top-relative-expression-ranked_500	TOX PRR36 KIF26B GLI3 DLX2 CNTLN PRDM16	1.17e-03	492	70	7	Facebase_RNAseq_e10.5_Maxillary Arch_500
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_500	TOX PRR36 GLI3 ID4 C11orf87 DLX2 CIT	1.18e-03	493	70	7	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_500
CoexpressionAtlas	dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_top-relative-expression-ranked_1000	MAGI2 IRF2BP2 KIF26B GLI3 RIN2 AFF1 CNTLN NR4A1 RUNX1	1.18e-03	797	70	9	gudmap_dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Medial Nasal Eminence_top-relative-expression-ranked_1000	HIVEP3 FNDC1 PRR36 RTL1 NPTXR GLI3 NINL C11orf87 GREB1 CNTLN	1.33e-03	979	70	10	Facebase_RNAseq_e10.5_Medial Nasal Eminence_1000
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_1000	DCAF1 CRACD MAP7D1 ZNF219 PRR36 NINL ID4 DLX2 RGL2 PRDM16	1.33e-03	979	70	10	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_1000
CoexpressionAtlas	FacebaseRNAseq_e9.5_Mandibular Arch_top-relative-expression-ranked_1000	DCAF1 CHCHD10 MAP7D1 NINL DLX2 GREB1 LMTK3 MBD6 RGL2 ZNF513	1.37e-03	983	70	10	Facebase_RNAseq_e9.5_Mandibular Arch_1000
ToppCell	Frontal_cortex-Neuronal-Inhibitory\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	SOX1 CRACD FNDC1 TMEM132E UBAP1L DLX2 EBF4	9.15e-09	169	70	7	78eb70dd916724e476eabccf18fb7fcec4210308
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SOX1 CRACD NPTXR DLX2 PARD3 CIT	5.84e-07	192	70	6	025fac36b862f9ca7f96fb4a1946c44ba7cbc382
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-2M-Radial_glial-gliogenic/outer_RGCs_and_astrocytes\|Organoid-2M / Sample Type, Dataset, Time_group, and Cell type.	SOX3 CHCHD10 TOX GLI3 DLX2 PRDM16	6.20e-07	194	70	6	7c6c0376603e5fcb64814fd6204d153629c2fbf5
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW10-Macroglial-Astrocyte\|GW10 / Sample Type, Dataset, Time_group, and Cell type.	SOX1 SOX3 BICRA GLI3 ID4 PRDM16	7.41e-07	200	70	6	98a994692440cb4f505b050276f0c8022c814a21
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW10-Macroglial\|GW10 / Sample Type, Dataset, Time_group, and Cell type.	SOX1 SOX3 BICRA GLI3 ID4 PRDM16	7.41e-07	200	70	6	ef222dc4a205d670172dae74990bdb952ac92e5b
ToppCell	droplet-Heart-nan-3m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAGI2 FNDC1 TOX ID4 DLX2	9.51e-06	180	70	5	da723df348d7b8449bb1124f23fe6fa706412adb
ToppCell	droplet-Heart-nan-3m-Neuronal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAGI2 FNDC1 TOX ID4 DLX2	9.51e-06	180	70	5	5b146a94708b3c3610542a4d0925f3f7a2b19185
ToppCell	droplet-Heart-nan-3m-Neuronal-cardiac_neuron\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAGI2 FNDC1 TOX ID4 DLX2	9.51e-06	180	70	5	50758b1e7be2e43f83c10ab106900c067e61f5f7
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Epithelial-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SOX1 FNDC1 ID4 DLX2 GREB1	1.00e-05	182	70	5	904804813849b7f7f716ba1554d33b07bc0a701e
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Epithelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SOX1 FNDC1 ID4 DLX2 GREB1	1.00e-05	182	70	5	5d8b7fe18286e27f0f50c5d2d9be56850e2cb8f4
ToppCell	5'-Adult-Appendix-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MAGI2 UBAP1L GREB1 PRDM16 EBF4	1.03e-05	183	70	5	5377b4fbd8fdfe68933b4c0965aa9525f7f31591
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_2\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CRACD NPTXR NINL DLX2 PARD3	1.09e-05	185	70	5	cefd81adb480c027545a5c78dcd05669783717f4
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SOX1 CRACD RIN2 DLX2 PARD3	1.17e-05	188	70	5	6ee3f8f94ea7bdf652c9575fc65bff08070093a4
ToppCell	E12.5-Mesenchymal-mesenchymal_fibroblast-tracheal_fibroblast\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TOX RIN2 ID4 PRDM16 FOXC2	1.17e-05	188	70	5	9b95730ddd13eb4624321bab3ab4989414977ca3
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PHLDB1 GLI3 RIN2 ID4 PRDM16	1.23e-05	190	70	5	2de8e4cfeee350a9a76af749d6ce58d948c129b8
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PHLDB1 GLI3 RIN2 ID4 PRDM16	1.27e-05	191	70	5	f3158cedf67e3b90aa94ea1f61c72c33aaa2d5ba
ToppCell	IPF-Stromal-SMC\|Stromal / Disease state, Lineage and Cell class	CABP1 CHCHD10 ID4 PRDM16 FOXC2	1.30e-05	192	70	5	9b06c7336624ef21f8e5393725b56038a8028e57
ToppCell	10x5'v1-week_12-13-Mesenchymal_adipo-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	FNDC1 NPTXR ID4 NR4A1 FOXC2	1.33e-05	193	70	5	cf2461af78f65616ce40d552ee9452295e3895ed
ToppCell	10x5'v1-week_12-13-Mesenchymal_adipo\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	FNDC1 NPTXR ID4 NR4A1 FOXC2	1.33e-05	193	70	5	6ef9007c9d18fb775d08fb20cdf954a28d54d7eb
ToppCell	10x5'v1-week_12-13-Mesenchymal_adipo-stroma-adipo-CAR\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	FNDC1 NPTXR ID4 NR4A1 FOXC2	1.33e-05	193	70	5	e4ea7ce011a80b81b841c907719aa532bed39d2e
ToppCell	droplet-Limb_Muscle-MUSCLE-1m-Mesenchymal-unknown\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CABP1 EFNB3 ID4 NR4A1 FOXC2	1.40e-05	195	70	5	0bdf845939bc4b8cc94f2808aea60f818425b076
ToppCell	(01)_IL1RL1+-(1)_GFP\|(01)_IL1RL1+ / shred by cell type by condition	MAP7D1 CITED4 CEBPB NACA ID4	1.43e-05	196	70	5	b598b1112242534e139318012b257ed3cb09da83
ToppCell	Non-neuronal-Non-dividing-Radial_Glia-tRG\|World / Primary Cells by Cluster	FNDC1 GLI3 ID4 NR4A1 PRDM16	1.47e-05	197	70	5	61749ccafeb938c310cff1de5ff924a1c794325a
ToppCell	COVID-19-Fibroblasts-Intermediate_pathological_FB\|COVID-19 / group, cell type (main and fine annotations)	MAGI2 CRACD KIF26B GLI3 PARD3	1.47e-05	197	70	5	f1c8936986123a3151140c374fcd62d6705c530b
ToppCell	Non-neuronal-Non-dividing-Radial_Glia-tRG-25\|World / Primary Cells by Cluster	FNDC1 GLI3 ID4 NR4A1 PRDM16	1.47e-05	197	70	5	9d4ffa3680f92c91d0a081f9a8ec5ebfec6bdcf6
ToppCell	Brain_organoid-organoid_Paulsen_bioRxiv-1_mon-Proliferating-Cycling_Progenitors\|1_mon / Sample Type, Dataset, Time_group, and Cell type.	IRF2BP2 EFNB3 GLI3 CNTLN PARD3	1.54e-05	199	70	5	358c4b3037f59378db8916a2fbe9ed4830cf1449
ToppCell	Neuronal-Inhibitory-iA-iA_2(LAMP5)-CA1-\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SOX1 CRACD TOX GLI3 PARD3	1.58e-05	200	70	5	ca5401b76ab014080914bf78042d368cf318effa
ToppCell	Neuronal-Inhibitory-iB-iB_4(SST)-CALB1--L1-3\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SOX1 CRACD KIF26B RIN2 PARD3	1.58e-05	200	70	5	f3c710f0fc8a7bfb5371d1aff6e3d8f266953153
ToppCell	Neuronal-Inhibitory\|Neuronal / cells hierarchy compared to all cells using T-Statistic	CRACD KIF26B RIN2 NINL PARD3	1.58e-05	200	70	5	9ff8647e2de0b538e15929dca88ebb20ff7ab043
ToppCell	Neuronal-Inhibitory-iB-iB_4(SST)-CALB1-\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SOX1 CRACD KIF26B RIN2 PARD3	1.58e-05	200	70	5	70a06fd7fb8de2c8ec3e3182e4476ced049daeae
ToppCell	Neuronal-Inhibitory-iA-iA_2(LAMP5)-CA1--L2-6\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SOX1 CRACD TOX GLI3 PARD3	1.58e-05	200	70	5	70c47d3bbe67d88c5b9dff99c33a603d25fa2ab0
ToppCell	Neuronal-Inhibitory-iA-iA_2(LAMP5)-CA1\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SOX1 CRACD TOX GLI3 PARD3	1.58e-05	200	70	5	40286010bd17cf9e34ecd5440953b072ebfae208
ToppCell	Neuronal-Inhibitory-iB-iB_4(SST)-CALB1\|Neuronal / cells hierarchy compared to all cells using T-Statistic	SOX1 CRACD KIF26B RIN2 PARD3	1.58e-05	200	70	5	1639982d9d994918f7912d12d9d7cfcbc9da4145
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Rspo4_Rxfp1_Chat\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	SOX3 ID4 DLX2 CIT	8.04e-05	145	70	4	78f5f4b96420c7f391e4d32a9ed151ed95fad90b
ToppCell	facs-Brain_Non-Myeloid-Hippocampus-24m-Macroglial-oligodendrocyte\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HNF1A PHLDB1 MAP7D1 EFNB3	9.17e-05	150	70	4	afd651c654e715414eff64cf3a37378d057a56a2
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Outer_Medullary_Collecting_Duct_Principal_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TOX KIF26B KIFC3 PRDM16	9.41e-05	151	70	4	10da94037225a71844281ddcb395072250a78094
ToppCell	Healthy_Control-Myeloid-Macrophages-FCN1_high\|Healthy_Control / Condition, Lineage, Cell class and cell subclass	CRACD GLI3 PLEKHA4 NR4A1	1.04e-04	155	70	4	cd2ccb4632713b4def3a1064599b78207e2e44c0
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Rspo4_Rxfp1_Chat\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	SOX3 ID4 DLX2 CIT	1.04e-04	155	70	4	3b8def9e8f66511736ea37f259511f7c8b7743af
ToppCell	Adult-Mesenchymal-myofibroblast_cell-D122\|Adult / Lineage, Cell type, age group and donor	CRACD PHLDB1 GLI3 FOXC2	1.12e-04	158	70	4	410fa08c9d880d27e80ec939fa5ba5a41dcb31ab
ToppCell	facs-Marrow-T_cells-18m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFRSF9 CITED4 TOX KIFC3	1.12e-04	158	70	4	9f0987eaf1766aadb5714b68df7a5d310ea5a57a
ToppCell	Frontal_cortex-Neuronal-Inhibitory-iN2(Gad1Gad2)\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	SOX1 CRACD TMEM132E DLX2	1.15e-04	159	70	4	7f29f9dcf25ffa1822b137c571e9ac16defc6292
ToppCell	facs-Marrow-T_cells-18m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFRSF9 CITED4 TOX KIFC3	1.15e-04	159	70	4	94bc6ab248a8f02ccbc0facd24e0c7e9fda687d2
ToppCell	droplet-Kidney-nan-18m-Lymphocytic-NK_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFRSF9 CITED4 TOX BICRA	1.18e-04	160	70	4	398f162e8a75c6cb5c3e4d1832e98d386e1f222b
ToppCell	droplet-Kidney-nan-18m-Lymphocytic-CD45____NK_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFRSF9 CITED4 TOX BICRA	1.18e-04	160	70	4	12aaab0291035f578e2433efd169ae72f393a5a5
ToppCell	PND01-03-samps-Myeloid-Macrophage-CD163+_Macrophage\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	EFNB3 TROAP CREB3L4 CIT	1.18e-04	160	70	4	4480a7d6bd48d06b4e5196faac868f31ab7ed3ad
ToppCell	Control\|World / Disease group and Cell class	TNFRSF9 CITED4 TOX VEGFB	1.21e-04	161	70	4	e3e72cda7cc70f06d669f26ccf06d51346d7136f
ToppCell	droplet-Kidney-KIDNEY-30m-Lymphocytic-CD45____NK_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HIVEP3 TNFRSF9 CITED4 TOX	1.23e-04	162	70	4	04a96442e0fcdb6a65b9e45044021677f9f53d38
ToppCell	droplet-Kidney-KIDNEY-30m-Lymphocytic-NK_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HIVEP3 TNFRSF9 CITED4 TOX	1.23e-04	162	70	4	7adb3e279526e1f21033c10af0a0058258f21842
ToppCell	facs-Heart-LA-18m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CRACD CHCHD10 CITED4 VENTX	1.32e-04	165	70	4	95866f7cc6eb1bb51a034a104a0eb2a53b0256f2
ToppCell	facs-Heart-LA-18m-Mesenchymal-atrial_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CRACD CHCHD10 CITED4 VENTX	1.32e-04	165	70	4	f8bfe336b9a4460b9349c01acd0bd3167812662f
ToppCell	droplet-Spleen-SPLEEN-30m-Lymphocytic-NK_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNFRSF9 CITED4 TOX KIFC3	1.32e-04	165	70	4	e24621c8d4dbafb407033d832fe9337f13feae34
ToppCell	PND01-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_prolif\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CRACD LRFN4 ADAMTS7 FOXC2	1.36e-04	166	70	4	49103b75c3e08656c5774f56fd00d7bd53eefcfb
ToppCell	Posterior_cortex-Neuronal-Inhibitory\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	SOX1 CRACD TMEM132E DLX2	1.39e-04	167	70	4	9a84f45345c75f2c8ff38a04245aadee2a26a240
ToppCell	droplet-Heart-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IRF2BP2 RIN2 NR4A1 FOXC2	1.45e-04	169	70	4	2e5bb6437bc9c614e337c5ffb6f6457cd9fc7f4c
ToppCell	P15-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	HIVEP3 CITED4 ADAMTS7 NFATC3	1.49e-04	170	70	4	ba4ba66b624089ed50a9083176386c7941b4c7a3
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	LMTK3 PARD3 PRDM16 CIT	1.49e-04	170	70	4	a2c738e441ced90eeeb1fcc6ca3269b918aaa298
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Ptprt_Pkp2\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	SOX1 ID4 DLX2 CIT	1.49e-04	170	70	4	14aa86a4f526ed6986afcb28c49225522055550c
ToppCell	5'-GW_trimst-1-SmallIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TROAP NPTXR LMTK3 PRR18	1.52e-04	171	70	4	05014cf6746e6663e376fdd681f1b43a7081c603
ToppCell	5'-GW_trimst-1-SmallIntestine-Mesenchymal-fibroblastic\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TROAP NPTXR LMTK3 PRR18	1.52e-04	171	70	4	d6114db2292fbb27b39d090d51fd305a135b1ccf
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Epithelial-neuronal_stem_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CRACD TROAP DLX2 ANKLE1	1.59e-04	173	70	4	f38bf7584e08d15a6e2c116b7c3551ba475a5e14
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHCHD10 ID4 KIFC3 PRDM16	1.62e-04	174	70	4	d0e3d15731de6c19c232e3aa492c39d8151cf4ed
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-5_VIP_TOX2\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SOX1 NPTXR RIN2 PARD3	1.73e-04	177	70	4	85e270b4a0b0da77ffe5987a099e827c02a4adf3
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_ZNF322P1\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FNDC1 RIN2 DLX2 PARD3	1.73e-04	177	70	4	84116796ca4c7007508c0f1a68a1135c7b922278
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FNDC1 RIN2 DLX2 PARD3	1.77e-04	178	70	4	3c973aac16988e88f5677d3d695dd772ccfd6570
ToppCell	facs-Marrow-KLS-24m-Hematologic-MPP_Fraction_B_+_C\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HNF1A PHLDB1 TROAP ANKLE1	1.81e-04	179	70	4	5297f7459b40ca780a1983fecc1bb9c035c7677e
ToppCell	PND14-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TROAP ANKLE1 CNTLN CIT	1.81e-04	179	70	4	54191c00b29f53b520cd3243b5791daa4a2c72d7
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MAGI2 FNDC1 EFNB3 GREB1	1.85e-04	180	70	4	f2f6e83127a4a415e65c76a35efa8175fbd5b5d9
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-5_VIP_TOX2\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SOX1 RIN2 NINL PARD3	1.89e-04	181	70	4	154d5e586cab25155c6d06dfe6ae01203b88e0fb
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Cortical_Collecting_Duct_Principal_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TOX KIF26B AFF1 PRDM16	1.89e-04	181	70	4	b7c85fbef3c06d5dc32a2a58f8d3dfabf1d79d9f
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	SOX1 CRACD TMEM132E DLX2	1.93e-04	182	70	4	f2a1784ffcba9b27132e0db21e574cbd8a0a6418
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-5_VIP_TOX2\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SOX1 CRACD RIN2 PARD3	1.93e-04	182	70	4	3d7a8d2ee2137b098248597058974ef5ae09c19e
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-6_VIP_RGS16\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SOX1 CRACD RIN2 DLX2	1.93e-04	182	70	4	724c33ad2fb525cbcfa5efa3362675eb42a5636d
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CRACD RIN2 NINL PARD3	1.93e-04	182	70	4	420a8fd30543e37a66ba0786215d056d308660d0
ToppCell	3'-Broncho-tracheal-Mesenchymal-Mesenchymal_Myocytic-tracheobronchial_smooth_muscle_cell-SM_activated_stress_response-SM_activated_stress_response_L.2.3.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CABP1 ID4 NR4A1 FOXC2	1.93e-04	182	70	4	97bb07478f56a937b490fba121ee603db64134a1
ToppCell	3'-Broncho-tracheal-Mesenchymal-Mesenchymal_Myocytic-tracheobronchial_smooth_muscle_cell-SM_activated_stress_response\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CABP1 ID4 NR4A1 FOXC2	1.93e-04	182	70	4	1c1a687f728341c209b048b6715bcddd0ac20069
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_ZNF322P1\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FNDC1 RIN2 PARD3 EBF4	1.93e-04	182	70	4	d3a037268f026eb2f84428b1821022503cef7756
ToppCell	Hippocampus-Neuronal-Inhibitory\|Hippocampus / BrainAtlas - Mouse McCarroll V32	SOX1 TMEM132E DLX2 CIT	1.93e-04	182	70	4	b54ae650c04dfd0759c5f5e752b9bf684dd36516
ToppCell	Globus_pallidus-Neuronal-Inhibitory\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	CRACD UBAP1L DLX2 EBF4	1.93e-04	182	70	4	04ccfa951eaa31fed6d140edb6c702d49363c5fa
ToppCell	droplet-Thymus-nan-3m-Lymphocytic-Double_negative_Thymocyte,_DN4_(Cd8-,_Cd4-),_some_undergoing_VDJ_recombination_\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HIVEP3 TNFRSF9 TOX NR4A1	1.97e-04	183	70	4	a0a3e4d07ac73dbbb1e019fd11e88ccffe6cf2ca
ToppCell	droplet-Lung-nan-3m-Myeloid-Alveolar_Macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IRF2BP2 CRACD RIN2 RUNX1	1.97e-04	183	70	4	ec3c05b9ce1e0fbb720e0dea41f1e28fd3fd878f
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Epithelial-Bergmann_glial_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SOX1 GLI3 ID4 GREB1	1.97e-04	183	70	4	99bb4ceb92f6467f2359a42ab2cff6df18825a30
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	FNDC1 GREB1 LMTK3 PML	2.01e-04	184	70	4	a6dee97ee4ef9d89e11d17339e0dadaea1210ce5
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Epithelial-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SOX1 FNDC1 ID4 GREB1	2.01e-04	184	70	4	6b0c110d8930df99043c3b99cf4d873985126960
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Epithelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SOX1 FNDC1 ID4 GREB1	2.01e-04	184	70	4	35928fc5f7bbf8c7b09181a2bd27e22dff42ec16
ToppCell	5'-GW_trimst-1.5-LargeIntestine-Neuronal-neuron_precursor\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SOX1 PRR36 ID4 DLX2	2.01e-04	184	70	4	7712f2e1fae5cdde2d4e355b860dc8536b28e4f6
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SOX1 CRACD RIN2 PARD3	2.01e-04	184	70	4	32473dbdb2de66391157c5814ef34e790806e4f2
ToppCell	droplet-Lung-nan-3m-Myeloid-alveolar_macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IRF2BP2 CRACD RIN2 RUNX1	2.01e-04	184	70	4	3261d767d5e3d9e9fbac22ad73ca14e44beed89c
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-5_VIP_TOX2\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SOX1 NPTXR RIN2 PARD3	2.05e-04	185	70	4	caf4f57f2db9ff72a652c8573e16e7ab180ffc05
ToppCell	pdx-Tumor_cells-T0\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	ATXN2 GREB1 RUNX1 PRDM16	2.05e-04	185	70	4	1d874608aa2062024323512f68889219471b2f00
ToppCell	COVID-19-Fibroblasts-Adventitial_FB\|COVID-19 / group, cell type (main and fine annotations)	MAGI2 GLI3 GREB1 PARD3	2.05e-04	185	70	4	a5aebf2b9b05b550d021272731d68af9a6b1229d
ToppCell	10x5'-lymph-node_spleen-Myeloid_Dendritic-Cycling_Dendritic\|lymph-node_spleen / Manually curated celltypes from each tissue	CABP1 TROAP CNTLN PRDM16	2.05e-04	185	70	4	912d8efdc37820dbb07736221a98af929e5a7c97
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_ZNF322P1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FNDC1 RIN2 PARD3 EBF4	2.05e-04	185	70	4	0b5a0df58ae2ad8261f40f152775747af4f3937a
ToppCell	droplet-Spleen-SPLEEN-1m-Lymphocytic-immature_NKT_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TROAP CNTLN PRDM16 CIT	2.05e-04	185	70	4	736bf89a7a1a840ab6920060f2d98598332065a0
ToppCell	droplet-Lung-LUNG-1m-Myeloid\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	IRF2BP2 CRACD CEBPB RUNX1	2.05e-04	185	70	4	53a5218c1e6eb12daccde3d6e02f337e2586d74c
ToppCell	droplet-Thymus-nan-3m-Lymphocytic-double_negative_T_cell\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HIVEP3 TNFRSF9 TOX NR4A1	2.10e-04	186	70	4	11929e36d8c9b4c4bc2f5e912f139f474f91ab00
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic-late_pro-B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EFNB3 TROAP TMEM132E FOXC2	2.10e-04	186	70	4	3993f1ef8a33b8a75dfd3db8d4845b5afbb0bb3d
ToppCell	pdx\|World / Sample and Cell Type and Tumor Cluster (all cells)	ATXN2 NFATC3 KIF26B GREB1	2.10e-04	186	70	4	de8e538c8767d41b8a52f5e58ba1affd4e7244c4
ToppCell	Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte\|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	IRF2BP2 CEBPB CNTLN PRDM16	2.10e-04	186	70	4	23b8d51d20b05795a73892d3e20e0f9b6a207820
ToppCell	facs-Marrow-T-cells-3m-Lymphocytic-late_pro_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EFNB3 TROAP TMEM132E FOXC2	2.10e-04	186	70	4	ec6d0c29e196e374baa96dd3d506f489c959e77e
ToppCell	facs-Trachea-18m-Mesenchymal-fibroblast-fibroblast_of_trachea-\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SOX1 MAGI2 HNF1A EBF4	2.10e-04	186	70	4	bdc87e4631a8ea73e262e541aa84a28f24c94b00
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	HIVEP3 PHLDB1 EFNB3 RIN2 AFF1 GREB1 NR4A1 RUNX1	1.23e-07	190	70	8	5602_UP
Drug	Piracetam [7491-74-9]; Up 200; 28.2uM; PC3; HT_HG-U133A	PHLDB1 ADAMTS7 BICRA DLX2 NR4A1 RUNX1 PML VEGFB	1.63e-07	197	70	8	5043_UP
Drug	Hyoscyamine (L) [101-31-5]; Down 200; 13.8uM; MCF7; HT_HG-U133A	PHLDB1 BICRA DLX2 GREB1 NR4A1 MLXIP PML	2.08e-06	192	70	7	2271_DN
Drug	PF-01378883-00 [351320-41-7]; Up 200; 10uM; PC3; HT_HG-U133A	CABP1 ZNF219 EFNB3 ADAMTS7 DLX2 RUNX1 PML	2.23e-06	194	70	7	6368_UP
Drug	(-)-Isoproterenol hydrochloride [5984-95-2]; Up 200; 16.2uM; MCF7; HT_HG-U133A	MAGI2 NR4A1 RUNX1 SRRM2 PRDM16 PML VEGFB	2.39e-06	196	70	7	3571_UP
Drug	Orlistat; Down 200; 10uM; PC3; HT_HG-U133A	DCAF1 HNF1A PER2 PRR36 NFATC3 DLX2 RUNX1	2.55e-06	198	70	7	6388_DN
Drug	Gabexate mesilate [56974-61-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A	DCAF1 PHLDB1 PRR36 DLX2 NR4A1 RUNX1 PML	2.55e-06	198	70	7	7357_UP
Drug	Dipyridamole [58-32-2]; Up 200; 8uM; MCF7; HT_HG-U133A	DCAF1 CABP1 PHLDB1 PER2 CNTLN SRRM2 PML	2.55e-06	198	70	7	5617_UP
Drug	PF-00539758-00 [351321-34-1]; Down 200; 10uM; PC3; HT_HG-U133A	HIVEP3 ZNF219 ID4 DLX2 KIFC3 CNTLN RUNX1	2.64e-06	199	70	7	6379_DN
Drug	Etanidazole [22668-01-5]; Up 200; 18.6uM; MCF7; HT_HG-U133A	HIVEP3 PHLDB1 PRR36 DLX2 GREB1 RUNX1 PML	2.64e-06	199	70	7	6072_UP
Drug	Timolol maleate salt [26921-17-5]; Up 200; 9.2uM; MCF7; HT_HG-U133A	DCAF1 CABP1 HNF1A KIF26B AFF1 RUNX1 VEGFB	2.64e-06	199	70	7	5280_UP
Drug	Cloxacillin sodium salt [642-78-4]; Up 200; 8.8uM; MCF7; HT_HG-U133A	HNF1A PHLDB1 EFNB3 PRR36 NPTXR AFF1 PML	2.73e-06	200	70	7	7483_UP
Drug	Helveticoside [630-64-8]; Up 200; 7.4uM; MCF7; HT_HG-U133A	NACA ID4 DLX2 NR4A1 RUNX1 PML	1.27e-05	167	70	6	6047_UP
Drug	trifluoperazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A	EFNB3 BICRA GREB1 NR4A1 MLXIP PML	1.94e-05	180	70	6	5584_UP
Drug	Pimozide [2062-78-4]; Up 200; 8.6uM; MCF7; HT_HG-U133A	HNF1A DLX2 NR4A1 RUNX1 PRDM16 PML	2.33e-05	186	70	6	3178_UP
Drug	Isoconazole [27523-40-6]; Up 200; 9.6uM; MCF7; HT_HG-U133A	EFNB3 DLX2 KIFC3 NR4A1 MLXIP RUNX1	2.33e-05	186	70	6	2218_UP
Drug	Ebselen [60940-34-3]; Up 200; 14.6uM; MCF7; HT_HG-U133A	MAGI2 RIN2 DLX2 NR4A1 RUNX1 PML	2.63e-05	190	70	6	3458_UP
Drug	Trifluridine [70-00-8]; Down 200; 13.6uM; HL60; HT_HG-U133A	PER2 TROAP BICRA RUNX1 CIT PML	2.70e-05	191	70	6	6136_DN
Drug	5707885; Down 200; 50uM; PC3; HT_HG-U133A	HIVEP3 HNF1A PRR36 NFATC3 KIFC3 RUNX1	2.70e-05	191	70	6	6390_DN
Drug	Drofenine hydrochloride [548-66-3]; Up 200; 11.4uM; MCF7; HT_HG-U133A	DCAF1 HIVEP3 NFATC3 DLX2 PML VEGFB	2.70e-05	191	70	6	6776_UP
Drug	Sulfacetamide sodic hydrate [6209-17-2]; Up 200; 15.8uM; PC3; HT_HG-U133A	HIVEP3 PHLDB1 NR4A1 RUNX1 SRRM2 PML	2.87e-05	193	70	6	1817_UP
Drug	trichostatin A; Down 200; 0.1uM; ssMCF7; HG-U133A	LRFN4 PER2 NACA GREB1 NR4A1 RUNX1	2.87e-05	193	70	6	413_DN
Drug	Cefmetazole sodium salt [56796-39-5]; Down 200; 8.2uM; HL60; HT_HG-U133A	PER2 RIN2 NR4A1 RUNX1 PML VEGFB	2.95e-05	194	70	6	2524_DN
Drug	Minocycline hydrochloride [13614-98-7]; Up 200; 8uM; PC3; HT_HG-U133A	HIVEP3 PHLDB1 ZNF219 NR4A1 RUNX1 VEGFB	2.95e-05	194	70	6	5077_UP
Drug	Niridazole [61-57-4]; Up 200; 18.6uM; MCF7; HT_HG-U133A	NFATC3 ID4 KIFC3 NR4A1 MLXIP PML	2.95e-05	194	70	6	3301_UP
Drug	radicicol; Down 200; 0.1uM; PC3; HT_HG-U133A	EFNB3 AFF1 KIFC3 NR4A1 RUNX1 PML	2.95e-05	194	70	6	5952_DN
Drug	Sulmazole [73384-60-8]; Down 200; 14uM; HL60; HT_HG-U133A	LRFN4 ZNF219 DLX2 RUNX1 PARD3 PML	3.04e-05	195	70	6	2153_DN
Drug	Meptazinol hydrochloride [59263-76-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A	SOX3 ZNF219 PER2 RUNX1 PML VEGFB	3.04e-05	195	70	6	7326_UP
Drug	Tadjakonine [11087-94-8]; Up 200; 7.4uM; MCF7; HT_HG-U133A	HNF1A PRR36 KIFC3 NR4A1 SRRM2 PML	3.04e-05	195	70	6	4424_UP
Drug	Solanine alpha [20562-02-1]; Down 200; 4.6uM; MCF7; HT_HG-U133A	PRR36 GLI3 AFF1 NR4A1 PARD3 PML	3.13e-05	196	70	6	4166_DN
Drug	Apramycin [37321-09-8]; Up 200; 7.4uM; HL60; HT_HG-U133A	GLI3 CNTLN MLXIP RUNX1 SRRM2 PML	3.13e-05	196	70	6	2914_UP
Drug	genistein; Up 200; 10uM; MCF7; HT_HG-U133A	PRR36 INTS1 RUNX1 PARD3 SRRM2 PML	3.13e-05	196	70	6	5232_UP
Drug	Rolitetracycline [751-97-3]; Up 200; 7.6uM; MCF7; HT_HG-U133A	HIVEP3 MAGI2 ADAMTS7 RUNX1 PARD3 SRRM2	3.13e-05	196	70	6	3369_UP
Drug	Sulfadimethoxine [122-11-2]; Down 200; 12.8uM; PC3; HT_HG-U133A	DCAF1 HIVEP3 NPTXR ID4 KIFC3 CNTLN	3.13e-05	196	70	6	3702_DN
Drug	2-propylpentanoic acid; Up 200; 200uM; PC3; HT_HG-U133A	MAGI2 TNFRSF9 ID4 KIFC3 NR4A1 RUNX1	3.22e-05	197	70	6	4438_UP
Drug	Guaifenesin [93-14-1]; Down 200; 20.2uM; MCF7; HT_HG-U133A	HNF1A NFATC3 KIFC3 RUNX1 PML VEGFB	3.22e-05	197	70	6	4371_DN
Drug	Delsoline [509-18-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A	CABP1 PHLDB1 RIN2 INTS1 RUNX1 VEGFB	3.22e-05	197	70	6	7212_UP
Drug	Suprofen [40828-46-4]; Down 200; 15.4uM; MCF7; HT_HG-U133A	DCAF1 TNFRSF9 RIN2 ID4 SRRM2 PML	3.22e-05	197	70	6	4123_DN
Drug	Azapropazone [13539-59-8]; Up 200; 13.4uM; HL60; HT_HG-U133A	LRFN4 ZNF219 KIF26B INTS1 NR4A1 PML	3.22e-05	197	70	6	3143_UP
Drug	Triflusal [322-79-2]; Up 200; 16.2uM; HL60; HG-U133A	HNF1A ATXN2 KIFC3 NR4A1 RUNX1 PARD3	3.22e-05	197	70	6	1717_UP
Drug	Crotamiton [483-63-6]; Up 200; 19.6uM; MCF7; HT_HG-U133A	TOX PRR36 INTS1 NR4A1 RUNX1 SRRM2	3.22e-05	197	70	6	3388_UP
Drug	Amoxicillin [26787-78-0]; Up 200; 11uM; MCF7; HT_HG-U133A	PHLDB1 TNFRSF9 KIF26B KIFC3 RUNX1 PML	3.22e-05	197	70	6	2620_UP
Drug	Epitiostanol [2363-58-8]; Up 200; 13uM; HL60; HT_HG-U133A	MAGI2 EFNB3 PER2 GLI3 RUNX1 PARD3	3.22e-05	197	70	6	2922_UP
Drug	Myosmine [532-12-7]; Up 200; 27.4uM; MCF7; HT_HG-U133A	HIVEP3 ADAMTS7 INTS1 RUNX1 CREBBP PML	3.22e-05	197	70	6	6055_UP
Drug	Pseudopelletierine hydrochloride [6164-62-1]; Up 200; 21uM; MCF7; HT_HG-U133A	LRFN4 PRR36 INTS1 NR4A1 SRRM2 PRDM16	3.22e-05	197	70	6	2766_UP
Drug	Benzthiazide [91-33-8]; Up 200; 9.2uM; MCF7; HT_HG-U133A	EFNB3 PER2 ID4 RUNX1 CREBBP PML	3.31e-05	198	70	6	3329_UP
Drug	Iproniazide phosphate [305-33-9]; Up 200; 14.4uM; MCF7; HT_HG-U133A	PHLDB1 EFNB3 PER2 NR4A1 RUNX1 CREBBP	3.31e-05	198	70	6	2288_UP
Drug	Tranylcypromine hydrochloride [1986-47-6]; Up 200; 23.6uM; PC3; HT_HG-U133A	EFNB3 NFATC3 ID4 CNTLN NR4A1 RUNX1	3.31e-05	198	70	6	7293_UP
Drug	Lincomycin hydrochloride [859-18-7]; Down 200; 9uM; MCF7; HT_HG-U133A	PHLDB1 GLI3 ID4 NR4A1 PML VEGFB	3.31e-05	198	70	6	5992_DN
Drug	Minoxidil [38304-91-5]; Down 200; 19.2uM; MCF7; HT_HG-U133A	HIVEP3 MAP7D1 EFNB3 PRR36 BICRA PML	3.31e-05	198	70	6	4800_DN
Drug	Brompheniramine maleate [980-71-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A	HIVEP3 TNFRSF9 NR4A1 RUNX1 PML VEGFB	3.31e-05	198	70	6	4131_DN
Drug	Neomycin sulfate [1405-10-3]; Up 200; 4.2uM; MCF7; HT_HG-U133A	DCAF1 TNFRSF9 NFATC3 KIF26B RUNX1 PRDM16	3.31e-05	198	70	6	7221_UP
Drug	Cephalexin monohydrate [23325-78-2]; Up 200; 11uM; MCF7; HT_HG-U133A	DCAF1 HIVEP3 PHLDB1 EFNB3 RUNX1 PML	3.31e-05	198	70	6	5615_UP
Drug	Vitexin [3681-93-4]; Down 200; 9.2uM; HL60; HT_HG-U133A	HIVEP3 ZNF219 NFATC3 DLX2 CNTLN RUNX1	3.31e-05	198	70	6	2155_DN
Drug	Naproxen [22204-53-1]; Up 200; 17.4uM; PC3; HT_HG-U133A	NFATC3 NPTXR KIFC3 NR4A1 RUNX1 PML	3.31e-05	198	70	6	6358_UP
Drug	Bromocryptine mesylate [22260-51-1]; Up 200; 5.4uM; MCF7; HT_HG-U133A	PHLDB1 EFNB3 GREB1 NR4A1 PML FOXC2	3.31e-05	198	70	6	1507_UP
Drug	Guanabenz acetate [23256-50-0]; Up 200; 13.8uM; MCF7; HT_HG-U133A	HIVEP3 EFNB3 KIFC3 RUNX1 CREBBP PML	3.31e-05	198	70	6	1544_UP
Drug	Orphenadrine hydrochloride [341-69-5]; Down 200; 13uM; MCF7; HT_HG-U133A	HIVEP3 PER2 PRR36 NPTXR ID4 RUNX1	3.31e-05	198	70	6	3883_DN
Drug	Ranitidine hydrochloride [66357-59-3]; Down 200; 11.4uM; MCF7; HT_HG-U133A	EFNB3 GREB1 NR4A1 MLXIP PRDM16 PML	3.31e-05	198	70	6	2251_DN
Drug	Carteolol hydrochloride [51781-21-6]; Up 200; 12.2uM; HL60; HT_HG-U133A	DCAF1 NFATC3 CNTLN NR4A1 RUNX1 PML	3.31e-05	198	70	6	1340_UP
Drug	valdecoxib; Down 200; 10uM; PC3; HT_HG-U133A	TOX PRR36 ID4 CNTLN RUNX1 PML	3.31e-05	198	70	6	6378_DN
Drug	Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A	PHLDB1 EFNB3 GREB1 NR4A1 MLXIP SRRM2	3.40e-05	199	70	6	3640_DN
Drug	Verapamyl hydrochloride [152-11-4]; Up 200; 8.2uM; MCF7; HT_HG-U133A	HIVEP3 KIFC3 CNTLN NR4A1 RUNX1 PML	3.40e-05	199	70	6	1509_UP
Drug	Phenethicillin potassium salt [132-93-4]; Up 200; 10uM; MCF7; HT_HG-U133A	DCAF1 HIVEP3 EFNB3 ADAMTS7 PRDM16 PML	3.40e-05	199	70	6	6105_UP
Drug	Amiprilose hydrochloride [60414-06-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A	DCAF1 HIVEP3 MAGI2 PER2 PARD3 PML	3.40e-05	199	70	6	4119_DN
Drug	Azathymine, 6 [932-53-6]; Up 200; 31.4uM; PC3; HT_HG-U133A	HNF1A PHLDB1 EFNB3 NFATC3 KIFC3 RUNX1	3.40e-05	199	70	6	3987_UP
Drug	2-propylpentanoic acid; Down 200; 50uM; MCF7; HG-U133A	DCAF1 HIVEP3 PHLDB1 EFNB3 NR4A1 RUNX1	3.40e-05	199	70	6	348_DN
Drug	Glipizide [29094-61-9]; Up 200; 9uM; HL60; HG-U133A	DCAF1 HIVEP3 ZNF219 NFATC3 BICRA DLX2	3.50e-05	200	70	6	2008_UP
Drug	Iohexol [66108-95-0]; Up 200; 4.8uM; MCF7; HT_HG-U133A	PHLDB1 PRR36 ID4 NR4A1 RUNX1 SRRM2	3.50e-05	200	70	6	3322_UP
Drug	Puromycin dihydrochloride [58-58-2]; Up 200; 7.4uM; MCF7; HT_HG-U133A	CEBPB PER2 ID4 DLX2 RUNX1	1.56e-04	165	70	5	3310_UP
Drug	fullerene C60	DCAF1 ZNF219 VENTX CEBPB EFNB3 PER2 DLX2 KIFC3 MBD6 RGL2 CIT CREBBP FOXC2 VEGFB	1.59e-04	1498	70	14	ctd:C069837
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	LRFN4 NACA GREB1 RUNX1 CREBBP	1.84e-04	171	70	5	6879_DN
Drug	Niclosamide [50-65-7]; Up 200; 12.2uM; HL60; HG-U133A	NACA AFF1 NR4A1 SRRM2 CREBBP	1.89e-04	172	70	5	1998_UP
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	LRFN4 GREB1 RUNX1 SRRM2 CREBBP	2.16e-04	177	70	5	6434_DN
Drug	Prenylamine lactate [69-43-2]; Up 200; 9.6uM; PC3; HT_HG-U133A	PHLDB1 CEBPB EFNB3 NR4A1 RUNX1	2.33e-04	180	70	5	5070_UP
Drug	Tamoxifen citrate [54965-24-1]; Up 200; 7uM; MCF7; HT_HG-U133A	EFNB3 RIN2 DLX2 NR4A1 RUNX1	2.39e-04	181	70	5	2212_UP
Drug	Thioguanosine [85-31-4]; Up 200; 12.6uM; MCF7; HT_HG-U133A	CEBPB EFNB3 NFATC3 NACA NR4A1	2.46e-04	182	70	5	4989_UP
Drug	Cantharidin [56-25-7]; Up 200; 20.4uM; HL60; HT_HG-U133A	ZNF219 EFNB3 NR4A1 RUNX1 PML	2.46e-04	182	70	5	3075_UP
Drug	Bisacodyl [603-50-9]; Up 200; 11uM; MCF7; HT_HG-U133A	EFNB3 ID4 DLX2 RUNX1 PARD3	2.52e-04	183	70	5	5677_UP
Drug	valinomycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	CEBPB DLX2 NR4A1 SRRM2 PRDM16	2.58e-04	184	70	5	5957_UP
Drug	valinomycin; Up 200; 0.1uM; PC3; HT_HG-U133A	CEBPB NFATC3 ID4 AFF1 DLX2	2.58e-04	184	70	5	5911_UP
Drug	Cloperastine hydrochloride [14984-68-0]; Up 200; 11uM; PC3; HT_HG-U133A	HNF1A LRFN4 CEBPB NR4A1 RUNX1	2.71e-04	186	70	5	4271_UP
Drug	Isotretinoin [4759-48-2]; Down 200; 13.4uM; HL60; HT_HG-U133A	LRFN4 NFATC3 DLX2 NR4A1 PML	2.71e-04	186	70	5	2407_DN
Drug	2-propylpentanoic acid; Down 200; 10000uM; MCF7; HG-U133A	HIVEP3 LRFN4 NACA GREB1 RUNX1	2.85e-04	188	70	5	345_DN
Drug	Econazole nitrate [24169-02-6]; Up 200; 9uM; MCF7; HT_HG-U133A	RIN2 ID4 AFF1 DLX2 NR4A1	2.85e-04	188	70	5	7427_UP
Drug	Mebendazole [31431-39-7]; Up 200; 13.6uM; MCF7; HT_HG-U133A	ADAMTS7 RIN2 GREB1 RUNX1 PML	2.92e-04	189	70	5	2300_UP
Drug	2-propylpentanoic acid; Up 200; 500uM; PC3; HT_HG-U133A	MAGI2 ID4 DLX2 NR4A1 RUNX1	2.92e-04	189	70	5	4464_UP
Drug	17-AAG; Up 200; 1uM; PC3; HT_HG-U133A	PER2 NFATC3 NACA ID4 RUNX1	2.92e-04	189	70	5	4450_UP
Drug	Bepridil hydrochloride [74764-40-2]; Up 200; 10uM; MCF7; HT_HG-U133A	DCAF1 MAGI2 NR4A1 RUNX1 PML	2.99e-04	190	70	5	5674_UP
Drug	Naftopidil dihydrochloride [57149-08-3]; Up 200; 8.6uM; HL60; HT_HG-U133A	GLI3 MLXIP RUNX1 SRRM2 PML	2.99e-04	190	70	5	2911_UP
Drug	Harmol hydrochloride monohydrate [40580-83-4]; Up 200; 15.8uM; MCF7; HT_HG-U133A	HIVEP3 PER2 PRR36 PARD3 PML	3.07e-04	191	70	5	2900_UP
Drug	Hexestrol [84-16-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A	PHLDB1 EFNB3 KIFC3 NR4A1 PML	3.07e-04	191	70	5	6077_UP
Drug	Megestrol acetate [595-33-5]; Up 200; 10.4uM; MCF7; HT_HG-U133A	HIVEP3 EFNB3 NR4A1 MLXIP RUNX1	3.14e-04	192	70	5	5013_UP
Drug	Etofenamate [30544-47-9]; Up 200; 10.8uM; MCF7; HT_HG-U133A	NR4A1 RUNX1 SRRM2 PRDM16 PML	3.14e-04	192	70	5	4108_UP
Drug	Acacetin [480-44-4]; Down 200; 14uM; MCF7; HT_HG-U133A	PHLDB1 NPTXR ID4 DLX2 PARD3	3.14e-04	192	70	5	6044_DN
Drug	Delcorine; Up 200; 8.4uM; PC3; HT_HG-U133A	DCAF1 MAGI2 PRR36 NFATC3 PML	3.14e-04	192	70	5	3715_UP
Drug	WY-14643; Down 200; 100uM; PC3; HG-U133A	PHLDB1 ATXN2 BICRA KIFC3 VEGFB	3.14e-04	192	70	5	464_DN
Drug	Tetrahydroalstonine [6474-90-4]; Up 200; 11.4uM; MCF7; HT_HG-U133A	PHLDB1 BICRA ID4 DLX2 RUNX1	3.22e-04	193	70	5	6209_UP
Drug	Simvastatin [79902-63-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A	EFNB3 MLXIP RUNX1 PRDM16 PML	3.22e-04	193	70	5	3340_UP
Drug	Clorgyline hydrochloride [17780-75-5]; Up 200; 13uM; MCF7; HT_HG-U133A	DCAF1 ID4 NR4A1 RUNX1 PML	3.22e-04	193	70	5	5005_UP
Disease	Osteitis Deformans	ZNF687 PML	1.81e-04	9	67	2	C0029401
Disease	triple-negative breast cancer	HNF1A ANKLE1	2.26e-04	10	67	2	EFO_0005537
Disease	psychological resilience measurement	TOX CNTLN	3.30e-04	12	67	2	EFO_0009945
Disease	migraine disorder, type 2 diabetes mellitus	GLI3 CREB3L4 CIT	3.49e-04	60	67	3	MONDO_0005148, MONDO_0005277
Disease	waist-hip ratio	TNFRSF9 CEBPB ATXN2 GLI3 CREB3L3 CNTLN RUNX1 PRDM16 PML VEGFB	4.25e-04	1226	67	10	EFO_0004343
Disease	alkaline phosphatase measurement	HIVEP3 IRF2BP2 HNF1A PHLDB1 ATXN2 NFATC3 GLI3 RUNX1 ATAT1	4.65e-04	1015	67	9	EFO_0004533
Disease	neuroimaging measurement	ATXN2 KIF26B GLI3 NINL AFF1 MBD6 PARD3 CREB3L4 PRDM16	6.74e-04	1069	67	9	EFO_0004346
Disease	cortical thickness	IRF2BP2 PHLDB1 ADAMTS7 ATXN2 GLI3 AFF1 MBD6 PARD3 FOXC2	8.96e-04	1113	67	9	EFO_0004840
Disease	Precursor B-cell lymphoblastic leukemia	AFF1 RUNX1	1.04e-03	21	67	2	C1292769
Disease	age of onset of childhood onset asthma	ATXN2 NFATC3 ID4	1.22e-03	92	67	3	OBA_2001015
Disease	cholesteryl esters:total lipids ratio, intermediate density lipoprotein measurement	HNF1A ATXN2 AFF1	1.68e-03	103	67	3	EFO_0008595, EFO_0020944
Disease	glucose measurement	HNF1A CEBPB ATXN2 GLI3 PRDM16	1.73e-03	380	67	5	EFO_0004468
Disease	Myeloid Leukemia, Chronic	PER2 RUNX1	1.98e-03	29	67	2	C0023473
Disease	Ischemic stroke, factor VII measurement	ATXN2 PARD3	1.98e-03	29	67	2	EFO_0004619, HP_0002140
Disease	lipoprotein A measurement	DCAF1 FNDC1 AFF1	2.14e-03	112	67	3	EFO_0006925
Disease	endometrial carcinoma	ATXN2 KIF26B ID4	2.19e-03	113	67	3	EFO_1001512

Protein segments in the cluster

Peptide	Gene	Start	Entry
SPAHSPPRTPTPGAS	ANKLE1	301	Q8NAG6
MAARSPPSPHPSPPA	CNTLN	1	Q9NXG0
PPRSGPATSPAGCHP	CREB3L3	101	Q68CJ9
SPLHPTPPPASTAAG	CREBBP	851	Q92793
RRTAPPPPGHASAGP	CABP1	41	Q9NZU7
HPGASASPPCASPPV	DLX2	221	Q07687
RVASSPAPPEGPSHP	CIT	1936	O14578
TGDRTPPPHSHPAAP	ADAMTS7	1091	Q9UKP4
PAPSPGPRDHLASDP	NR4A1	11	P22736
ASAPSAPTAHPQPRP	DCAF1	921	Q9Y4B6
DLGSPPAPHASSSPP	MBD6	241	Q96DN6
PARPPLSALAPPHGS	MBD6	826	Q96DN6
IHPRPPPPRDSGSHS	GLI3	646	P10071
GEVPAADSPSPPHSP	MAGEA2	51	P43356
GLAPFSPSHPAPPSD	MAGI2	1261	Q86UL8
PSAISRHSPGPTPQP	GREB1	1186	Q4ZG55
RPSAAAKPSGHPPPG	INTS1	11	Q8N201
RPSRPPSHPSAHGSP	ATXN2	591	Q99700
SPVPAAAPAHSPSPA	KIF26B	1006	Q2KJY2
PPAHSAPRPGTLSSP	LMTK3	436	Q96Q04
APGTVAAPPAPPHAS	PER2	861	O15055
AHSSPGLPPPALSPS	HNF1A	301	P20823
PPPAASKGAPATPHL	FOXC2	186	Q99958
HPAGTCPAAPPRTPL	ID4	126	P47928
PPALPGAPAASAHPL	NPTXR	71	O95502
RAHASAAPPPPRAGP	MLXIP	51	Q9HAP2
RPPSSPPQACPRAHG	EBF4	561	Q9BQW3
RPASRPAAPSAHPPA	CHCHD10	11	Q8WYQ3
HPPPSAAAPAPAPSG	CHCHD10	26	Q8WYQ3
PPPGSSPRASHVPSR	FNDC1	1246	Q4ZHG4
PPAPAPAPASSGQHH	CEBPB	101	P17676
SRSVPVAHPGPPPAS	CRACD	926	Q6ZU35
VAHPGPPPASSQTPA	CRACD	931	Q6ZU35
RPASPCPSPGPGHTL	MAP7D1	476	Q3KQU3
TPPAHPPPRSSSLGN	ATAT1	261	Q5SQI0
PSGTPTAPSHAPAPA	BICRA	1006	Q9NZM4
LCPRARPPGPHSSPN	EFNB3	61	Q15768
AQTGSAPPRPAAPHP	SAC3D1	6	A6NKF1
PPPPAHRGPADSLST	IRF2BP2	261	Q7Z5L9
APPRPAGSGHSPART	PRR18	91	Q8N4B5
CHPDSPPAPRATSSP	CREB3L4	96	Q8TEY5
HPSGKPPSAPASAPQ	PARD3	426	Q8TEW0
VSPHHPAPTPNPRAS	RUNX1	211	Q01196
EAPPSHTAATHPPRP	RTL1	1266	A6NKG5
ADPSHLSPPASSPRP	RGL2	596	O15211
PPDSLAHRPPSSAPT	SOX3	31	P41225
SSPESPKPAPAPGSH	SRRM2	436	Q9UQ35
RSHPASPSPPGPQAS	TMEM132E	26	Q6IEE7
PPAPSGDTAPPARPH	PLEKHA4	256	Q9H4M7
APAPASPAARPFPHT	KIFC3	36	Q9BVG8
AVSPPHLDGPPSPRS	PML	516	P29590
GPSARGTPRAPAHPS	PRR36	256	Q9H6K5
SRPHPGSLPFSTAPP	PRDM16	491	Q9HAZ2
EPSGSPPAPAHSRAP	SOX1	321	O00570
PAPAPAPASHGPSER	NINL	891	Q9Y2I6
SSSKAPRAPPEAPHP	AFF1	566	P51825
APSAAAPPPPAHALG	CITED4	116	Q96RK1
PPPPASSPQGAHAAS	C11orf87	166	Q6NUJ2
APPHSPPSVLSSRGP	ZNF513	511	Q8N8E2
APPPSSESRPPCHGG	RIN2	411	Q8WYP3
SVTPPAPAREPGHSP	TNFRSF9	171	Q07011
AQFPSPPPAPHGRSA	HIVEP3	826	Q5T1R4
PPPAPHGRSAHSLQP	HIVEP3	831	Q5T1R4
APPPGPPHALRADSS	HIVEP3	1881	Q5T1R4
PPVATPSGPHSNRTP	TROAP	411	Q12815
SHPLASSPLSGPPSP	NFATC3	931	Q12968
TGPAAASPHSSPPPL	PHLDB1	936	Q86UU1
HPAAPASPPRPSTAG	UBAP1L	206	F5GYI3
APGAPSPADITHPTP	VEGFB	156	P49765
SPADITHPTPAPGPS	VEGFB	161	P49765
THPTPAPGPSAHAAP	VEGFB	166	P49765
GDHSDPLPPSAPSPT	ZNF687	171	Q8N1G0
PHNSPSPPGSKSATP	TOX	201	O94900
PRAPSGHLAPSPPAF	ZNF219	6	Q9P2Y4
ASHPPTPGRPSLGPA	VENTX	226	O95231
NGGPSPTPKAHPPRS	LRFN4	561	Q6PJG9
PHKGAPTTPAATPPS	NACA	1121	E9PAV3